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9ABSTRACT
Acute heart failure syndrome represents a prominent and growing health problem all around the 
world. Ideally, medical treatment for patients admitted to hospital because of this syndrome, in 
addition to alleviating the acute symptoms, should also prevent myocardial damage, modulate 
neurohumoral and inflammatory activation, and preserve or even improve renal function. 
Levosimendan is a cardiac enhancer having both inotropic and vasodilatory effects. It is approved 
for the short-term treatment of acutely decompensated chronic heart failure, but it has been shown to 
have beneficial clinical effects also in ischemic heart disease and septic shock as well as in 
perioperative cardiac support.  
In the present study, the mechanisms of action of levosimendan were studied in isolated guinea-pig 
heart preparations: Langendorff-perfused heart, papillary muscle and permeabilized cardiomyocytes 
as well as in purified phosphodiesterase isoenzyme preparations. Levosimendan was shown to be a 
potent inotropic agent in isolated Langendorff-perfused heart and right ventricle papillary muscle. In 
permeabilized cardiomyocytes, it was demonstrated to be a potent calcium sensitizer in contrast to 
its enantiomer, dextrosimendan. It was additionally shown to be a very selective phosphodiesterase 
(PDE) type-3 inhibitor, the selectivity factor for PDE3 over PDE4 being 10000 for levosimendan. 
Irrespective of this very selective PDE3 inhibitory property in purified enzyme preparations, the 
inotropic effect of levosimendan was demonstrated to be mediated mainly through calcium 
sensitization  in the isolated heart as well as the papillary muscle preparations at clinically relevant 
concentrations. In the isolated Lagendorff-perfused heart, glibenclamide antagonized the 
levosimendan-induced increase in coronary flow (CF). Therefore, the main vasodilatory mechanism 
in coronary veins is believed to be the opening of the ATP-sensitive potassium (KATP) channels. In 
the paced hearts, CF did not increase in parallel with oxygen consumption (MVO2), thus indicating 
that levosimendan had a direct vasodilatory effect on coronary veins. The pharmacology of 
levosimendan was clearly different from that of milrinone, which induced an increase in CF in 
parallel with MVO2.
In conclusion, levosimendan was demonstrated to increase cardiac contractility by binding to 
cardiac troponin C and sensitizing the myofilament contractile proteins to calcium, and further to 
induce coronary vasodilatation by opening KATP channels in vascular smooth muscle. In addition, 
the efficiency of the cardiac contraction was shown to be more advantageous when the heart was 
perfused with levosimendan in comparison to milrinone perfusion. 
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1 INTRODUCTION 
Acute heart failure syndromes are a most common cause of hospitalization all over the world with a 
dismal long-term prognosis (Goldberg et al. 2007). According to the European Society of 
Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure (HF) 
issued in 2008, acute heart failure is defined as ‘rapid onset or change in the signs and symptoms of 
HF, resulting in the need for urgent therapy’ (Dickstein et al. 2008). HF is defined as a syndrome in 
which patients should have the following features: Typical symptons like breathlessness at rest or on 
exercise, fatigue, tiredness and ankle swelling; typical signs like tachycardia, tachypnoea, 
pulmonary rales, pleural effusion, raised jugular venous pressure, peripheral oedema and 
hepatomegaly and; objective evidence of a structural or functional abnormality in the heart at rest 
like cardiomegaly, third heart sound, cardiac murmurs, abnormality on the echocardiogram and 
raised natriuretic peptide concentration (Dickstein et al. 2008). Acute heart failure (AHF) may be 
either new HF or worsening of pre-existing chronic HF. Patients differ in terms of their clinical 
presentation, pathophysiology, prognosis, and therapeutic options (Flaherty et al. 2009). Primarily 
the symptoms of AHF are the result of severe pulmonary congestion due to elevated left ventricular 
filling pressure and/or diastolic dysfunction, which can be related to low cardiac output. AHF 
patients can have both preserved and reduced ejection fraction (EF) and be suffering from a variety 
of cardiovascular conditions such as coronary heart disease (CHD), hypertension, valvular heart 
disease and atrial arrhythmias (Gheorghiade et al. 2005c). In addition, noncardiac conditions like 
renal dysfunction, diabetes and anaemia are often present (Gheorghiade et al. 2005c). 
AHF can be categorized into 6 clinical distinct entities, which can overlap with each other: 
worsening or decompensated chronic HF, pulmonary oedema, hypertensive HF, cardiogenic shock, 
isolated right HF and, acute coronary syndrome (ACS) and HF (Dickstein et al. 2008) (Fig. 1.). The 
majority of patients presenting with AHF have coronary artery disease (CAD) (Flaherty et al. 2009). 
These patients can be divided into two groups, those with acute CAD and those with underlying or 
chronic CAD. Thus, therapeutic strategies can be designated according to appearance of CAD. 
The most common entities of symptoms of AHF patients admitted to the intensive care unit are 
acutely decompensated chronic heart failure and pulmonary edema with elevated systemic blood 
pressure (Gheorghiade et al. 2005c). Conventionally, the primary therapeutic management for acute 
HF deterioration are reduction of PCWP and/or increase of cardiac output, but blood pressure 
control, myocardial protection, neurohormonal modulation, and preservation of renal function may 
also be needed. According to Finnish Acute Heart Failure Study (FINN-AKVA), acute congestion 
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(63.5%) was the most common manifestation of AHF and over one quarter of the patients (26.3%) 
displayed pulmonary oedema. The rest had either cardiogenic shock (2.3%) or hypertensive crisis 
(3.1%) or right ventricular failure (4.8%). Furthermore, half of the patients had a history of HF 
(Siirila-Waris et al. 2006). 
According to the ESC Guidelines (Dickstein et al. 2008), inotropic agents should be considered in 
patients with low output state, in the presence of signs of hypoperfusion or congestion despite the 
use of vasodilators and/or diuretics to alleviate the symptoms. Traditionally inotropes are 
categorised into three classes: cardiac glycosides (e.g. digitalis); sympathomimetic amines having -
adrenergic activity (e.g. dopamine, dobutamine, norepinephrine and epinephrine) and; 
phosphodiesterase inhibitors (PDEIs) (e.g. milrinone and enoximone) (Braunwald 1992). These 
inotropic agents generally improve the hemodynamic status of the AHF patients, but on the other 
hand, have not been shown to improve survival, in fact may even worsen survival (Amidon and 
Parmley 1994; Thackray et al. 2002; Felker et al. 2003) probably due to elevating intracellular 
calcium levels, an action which is crucial to their mechanism of inotropic action (Papp et al. 2005). 
Therefore, these drugs should be withdrawn as soon as the desired hemodynamic effects are reached 
(e.g. adequate organ perfusion or reduced congestion) (Dickstein et al. 2008). 
One of the latest entries in the family of cardiac enhancers is levosimendan, a novel compound 
having both inotropic and vasodilatory effects (Parissis et al. 2008). The present studies were 
designed to characterize the mechanisms of action of levosimendan and to compare its inodilatory 
effects to those of phosphodiesterase inhibitors, acting via a different mechanism of action. The ex-
vivo experiments were done in isolated heart preparations, a technique which allows untangling the 
inotropic and vasodilatory effects of the drugs studied. Levosimendan increases cardiac contractility 
by enhancing the sensitivity of the contractile proteins to calcium ions (Pollesello et al. 1994), and 
exerts a vasodilatory effect by opening adenosine triphosphate ATP-sensitive potassium (KATP)
channels in vascular smooth muscle (Yokoshiki et al. 1997). Due to its novel mechanism of action, 
which is not dependent upon an increase in the intracellular level of calcium, it is believed to be 
more beneficial than the other inodilators in being able to reduce both morbidity and mortality. 
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Figure 1. Clinical classification of AHF. Acute heart failure (AHF); Acute coronary syndrome (ACS). Modified from 
(Dickstein et al. 2008) Eur Heart J 29(19): 2388-442.
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2 REVIEW OF THE LITERATURE 
2.1 Regulation of the cardiac contraction 
Two characteristic intrinsic mechanisms, independent of neural and humoral influences, determine 
the contractile regulation of cardiac myocytes; the Frank- Starling mechanism and the positive 
force-frequency relationship. The Frank-Starling mechanism is defined as the ability of the heart to 
change its force of contraction and therefore the stroke volume in response to changes in venous 
return, i.e. an increase in ventricular wall stretch, leading to an increase in contractile force. The 
positive force-frequency relationship, i.e. increased heart rate which induces an increase in 
contractile force, also leads to an increase in stroke volume. The immediate response to the stretch 
(Frank- Starling mechanism) does not increase the Ca2+ transient, but is followed by slowly 
developing increase in intracellular calcium concentration [Ca2+]i, probably due to the increase in 
Ca2+ binding affinity to troponin C induced by the force generation (Endoh 2008). The force-
frequency relationship is, in turn, associated with the mobilization of [Ca2+]i. Furthermore, cardiac
muscle contracts phasically, so that the difference between systolic and diastolic [Ca2+]i, determine 
the effect on the left ventricular function. Thus, heart muscle contraction can be enhanced by 
increasing the [Ca2+]i  in the cardiomyocytes. Relaxation, in turn, depends on how fast Ca2+ is 
extruded or taken back into the sarcoplasmic reticulum (SR). Myocyte [Ca2+]i can be increased by 
increasing intracellular levels of cyclic adenylate monophosphate (cAMP) or by affecting the 
sodium-calcium exchanger (NCX). The increased amount of Ca2+ is accumulated into the cytosol 
and stored into the SR. This Ca2+ is then released from SR by each heart-beat-cycle, which leads to 
increased contractility of the heart (Braunwald 1992). 
Contraction of the cardiac cell 
Skeletal and cardiac muscles are both composed of striated muscle cells and the sarcomere structure 
and the general mechanism involved in the muscle contraction is the same. The striated muscle cell 
contains myofibrils formed by repeating units of sarcomeres. They are arranged in series, which are 
composed of two type parallel filaments, a thin filament and a thick filament. The thick filament is a 
polymer, composed of myosin molecules which in turn consists of two heavy and four light chains. 
A bundle of myosin heavy chain coiled tails forms the backbone of the thick filament. The globular 
heads of the heavy chain N-terminus named as subfragment 1 (S1) are located in the thick filament 
at regular intervals and interact with the thin filaments to form strong crossbridges. The thin 
filament, in turn, has a two-stranded helical structure. The backbone of the thin filament is 
14
composed of polymerized globular actin monomers (G-actin). Actin monomers consist of two 
equal-sized domains which are available for myosin interaction or interact with the corresponding 
sub-domains of the adjacent strand (Holmes et al. 1990). 
A series of regulatory proteins modulate the interaction between the thick and thin filaments. The 
most elongated of them, tropomyosin (Tm) overlaps with the neighboring tropomyosins in a head-
to-tail configuration. The overlapping regions of adjacent tropomyosins are mainly responsible for 
the affinity of Tm for actin. It binds to the actin filament by electrostatic interaction (Lorenz et al. 
1995). Instead of being fixed in one position, Tm rolls over the surface of the thin filament 
depending on the phase of the contraction cycle. This movement is influenced by Ca2+ and it affects 
myosin S1 binding to actin (Gordon et al. 2000; Gordon et al. 2001; Sorsa et al. 2004). Every 
tropomyosin is spatially coupled to a troponin complex (Tn), and together they form the calcium 
dependent trigger of the contractile apparatus. Tn consists of a Tm binding unit troponin T (TnT), an 
actomyosin ATPase inhibitory unit troponin I (TnI), and a calcium-binding unit troponin C (TnC). 
Striated-muscle troponin C is expressed in two isoforms in vertebrates, in fast skeletal muscle there 
is skeletal troponin C (sTnC) and in slow skeletal and cardiac muscles it is cardiac troponin C 
(cTnC). TnT is an asymmetric protein that attaches the Tn complex to a defined position on the thin 
filament. It is needed for full, Ca2+-dependent activity of the thin filament. The interaction of TnT 
with Tm is calcium sensitive. Calcium-binding to TnC initiates the cascade of events leading to 
muscle contraction. The interaction between TnC and TnI is essential for further transmission of the 
contraction signal to the other components of the thin filament (Sorsa et al. 2004). 
Mechanism of action of cardiotonic agents
The adrenergic beta1-receptor (1-AR) is the main adrenergic receptor type in heart cells. It is 
stimulated by the endogenous norepinephrine (NE), released from the sympathetic nerve-endings. 
Drugs that enhance NE release can be inotropic, but mainly the receptor is stimulated by the beta-
adrenergic agonists. Stimulation of 1-AR activates  adenylyl cyclase (AC) due to the G-stimulatory 
protein (Gs). The activation of AC increases the  intracellular levels of cAMP, which activates 
cAMP dependent protein kinase (PKA). PKA, in turn, phosphorylates L-type calcium channels 
leading to their opening and increase in [Ca2+]i. Increased [Ca2+]i triggers the release of Ca2+ from 
SR via ryanodine receptors and furthermore, there is increased force generation by the actin-myosin 
apparatus when Ca2+ binds to the cTnC (Sorsa et al. 2004).  
PDE inhibitors increase the amount of intracellular cAMP by inhibiting its breakdown. Thus, this 
mechanism is downstream to 1-AR stimulation and acts in a parallel manner with it. In all, 11 
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families of PDE enzymes have been identified, 5 of them in heart tissue. They differ in terms of 
their affinity for cAMP and cGMP, cellular expression, intracellular localization, and mechanisms 
of regulation. Their function is dependent on their compartmentation with protein kinases and other 
proteins related to signal transduction cascades (Fischmeister et al. 2006; Vandecasteele et al. 2006). 
Two families, PDE3 and PDE4, are the most important in the regulation of the cardiac contractility. 
PDE4 is cAMP specific, but PDE3 has a very high affinity for both cAMP and cGMP. However, its 
turnover rate for cGMP is much lower than its turnover rate for cAMP (Shimizu et al. 2002). 
Thereby, PDE3 may function primarily as a cGMP-inhibited cAMP phosphodiesterase. Inhibition of 
the cAMP-hydrolytic activity of PDE3 by cGMP contributes to the potentiation of delayed rectifier 
K+ currents and L-type Ca2+ currents in cardiac myocytes (Shimizu et al. 2002; Movsesian et al. 
2008).
Cardiac glycosides, like digoxin, bind to the -subunit of the sodium/potassium ATPase (Na+/K+
pump) in the extracellular membranes of the myocytes and inhibit its function. The inhibition of the 
Na+/K+ pump causes an increase in the intracellular sodium concentration [Na+]i in the myocytes, 
which leads further to an elevation in [Ca2+]i by the NCX. Basically, NCX that normally extrudes 
Ca2+ from the cell (forward mode), also brings Ca2+ into the cell (reverse mode) during membrane 
depolarization in the resting phase of the cardiac action potential (Iwamoto et al. 2007). NCX can 
run in the reverse mode also when Na+ accumulates into the cytosol. As a result of the inhibition of 
the Na+/K+ pump, Ca2+ accumulates in the cytosol and is then stored in the SR. In principle, the 
inhibition of the forward mode of NCX can also cause an inotropic effect. 
The above-mentioned mechanisms increase the cytosolic calcium concentration [Ca2+]i and thus, 
result in higher demands for oxygen and elevated risk of arrhythmias, cell injury, apoptosis or 
necrosis due to Ca2+ overload. An alternative idea is to enhance the response of myofilaments to 
calcium without an increase in the [Ca2+]i, and thus, have a positive inotropic effect on cardiac 
contractility. Calcium sensitizers can increase the Ca2+ affinity to troponin, like pimopendan. They 
can stabilize the Ca2+ bound conformation of troponin C, like levosimendan or furthermore, they can 
have a direct effect on the cycling rate of actinmyosin cross-bridges, lowering the threshold of 
[Ca2+]i needed for actin sliding, like MCI-154 (Kass and Solaro 2006). 
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Role of stereoisomerism on the pharmacodynamic action 
The symmetry of a molecule determines its chirality. A molecule is chiral when it is non-
superposable on its mirror image. Enantiomers are two stereoisomers that are mirror images of each 
other. However, a chiral molecule is not necessarily asymmetric. Different enantiomers of a 
compound have the same physical properties, but they rotate polarized light in different directions 
and interact differently with optical isomers of other compounds. Therefore, the enantiomers of a 
compound may have substantially different biological effects. A mixture of equal parts of the 
enantiomers is called racemic. 
Many drugs are chiral and only one of the enantiomers are biologically active or more effective than 
the other. A good example is adrenaline of which the natural form is the (R)-()-L-adrenaline. An 
enantiomer can be named by the direction in which it rotates the plane of polarized light. If it rotates 
the light clockwise the enantiomer is labeled (+), if counter-clockwise it is labeled (). An optical 
isomer can be named by the D/L system, a spatial configuration of its atoms relating the molecule to 
glyceraldehyde. The R/S system is the most important nomenclature system for symbolizing 
enantiomers, which does not involve a reference molecule such as glyceraldehyde. It labels each 
chiral center R or S according to the CIP system(Cahn Ingold Prelog priority rules) (Cahn et al. 
1966). The R/S system has no fixed relation to the (+)/(-) or the D/L systems. 
Classical examples of cardiotonic drugs, which have two enantiomers are propranolol and 
carvedilol. Only L-propranolol is a 1-AR antagonist, whereas D-propranolol has little binding 
affinity. However, both isomers possess a local anesthetic effect. Furthermore, S(-) isomer of 
carvedilol is 100 times more potent as 1-AR antagonist than R(+) isomer. However, both of the 
isomers are approximately equipotent as adrenergic 1-receptor (1-AR) antagonists. 
2.2 Regulation of the vascular resistance 
Vascular resistance is dependent on contraction and relaxation of  smooth muscle myocytes. The 
molecular mechanisms involved in the contraction-relaxation process in the smooth muscle cells 
and its modulation can be manipulated pharmacologically in many ways. Smooth muscle contracts 
tonically, thereby the vascular tone is in direct proportion to a function of  [Ca2+]i itself, not to the 
difference between systolic and diastolic [Ca2+]i. Agents that increase [Ca2+]i in vascular smooth 
muscle cells are vasoconstrictors, while agents that decrease [Ca2+]i  in vascular smooth muscle cells 
are vasodilators. 
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Mechanism of action of vasodilatory agents 
The inhibition of L-type calcium channels leads to a decrease in vascular myocyte [Ca2+]i. Less Ca2+
is bound to calmodulin, which decreases the activation of myosin kinase and further reduces the 
phosphorylation of myosin thick filament. L-type calcium channels are voltage-dependent and are 
inhibited by three type of chemical substances, the phenylalkylamines (like verapamil), the 
dihydropyridines (like nifedipide) and by benzothiazephines (like diltiazem). They are vasodilators, 
but verapamil is used also as an antiarrhythmic agent. 
Calcium release via inositol trisphosphate (IP3)-sensitive Ca2+ channels from SR is another source 
of [Ca2+]i in vascular myocytes. IP3 is generated from phosphatidylinositol when phospholipase C is 
activated by Gq-coupled receptors i.e. 1-adrenergic, angiotensin, and endothelin receptors. M1/M3 
muscarinic receptors and ETB endothelin-receptor are also coupled to inositol triphosphate (IP3)
generation, but in endothelial cells. Increased endothelial [Ca2+]i leads to vasodilatation contrary to 
the situation in vascular smooth muscle cells (see below, cGMP-dependent vasodilatation). The 
main drug categories acting ultimately through IP3 generation are angiotensin converting enzyme 
inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), endothelin receptor antagonists and 
1-AR antagonists. 
The formation of cGMP from GTP by guanylate cyclase (GC) is analogous to the formation of 
cAMP from ATP by AC. Two forms of GC exist, a soluble enzyme and a membrane-bound 
enzyme. GC activates cGMP-dependent protein kinase (PKG), which phosphorylates the IP3
receptor-associated cGMP kinase substrate (IRAG). Phosphorylation of IRAG further reduces IP3-
induced Ca2+ release, leading to relaxation of vascular myocytes. PKG also phosphorylates K+
channels and thereby, hyperpolarizes the cell membrane and decreases Ca2+ influx through L-type 
channels. In addition, PKC phosphorylates myosin light chain phosphatase and so, dephosphorylates 
the myosin ATPase and reduces the contraction of vascular myocytes. Furthermore, it 
phosphorylates Gq-protein and thus, inhibits IP3 formation. Soluble GC is a target for nitric oxide 
(NO), synthesised endogenously from arginine and oxygen by nitric oxide synthase (NOS) enzymes 
or formed by reduction from organic nitrates and then released from endothelial cells. Nitroglycerin 
(or glyceryl trinitrate) and sodium nitroprusside, are both sources of NO and thus, common 
vasodilatory agents. The natriuretic peptides (ANP, BNP and CNP), instead, bind to the specific NP 
receptors (NPRs). Three subtypes of NPRs have been characterized, namely NPR1, NPR2 and 
NPR3. Two of them, NPR1 and NPR2, contain the GC catalytic domain (membrane bound GC). 
ANP and BNP selectively stimulate NPR1, whereas CNP activates primarily NPR2. All three NPs 
18
bind to NPR3, which clears them from the circulation through receptor-mediated internalization and 
degradation (Potter et al. 2006; Potter et al. 2009). Moreover, PDE5 is essentially the most cGMP 
specific of the cardiac phosphodiesterases. The benefits of PDE5 inhibition in heart failure originate 
from a decrease of the right ventricle afterload resulting from pulmonary vasodilatation (Movsesian 
et al. 2008). 
The increase in the cAMP content in smooth muscle cells evokes vasodilatation. The cAMP level 
increases when vascular 2-adrenergic receptors are stimulated. Instead of PKA, cAMP activates 
PKG in vascular myocytes. PKG has a much lower affinity for cAMP than for cGMP, but cAMP 
levels can rise high enough to activate PKG in smooth muscle cells, despite its relatively low 
affinity for cAMP. In this manner, vasodilatation occurs when PDE3 is inhibited and cAMP 
hydrolysis is restricted. 
Activation of potassium channels in vascular smooth muscle cells results in membrane 
hyperpolarization and thus, a decrease Ca2+ influx through L-type channels and further 
vasodilatation (Brayden 2002). Four major classes of potassium channels have been classified: 
calcium-activated potassium channel (BKCa), inwardly rectifying potassium channels (IRK), two-
pore-domain potassium channels and voltage-gated potassium channels (KV). KATP channels belong 
to the IRK channels, containing four pore-forming Kir6.x subunits and a large regulatory 
sulfonylurea receptor (SUR) (Aguilar-Bryan et al. 1998; Brayden 2002). They appear to be tonically 
active in some vascular beds, e.g. in the coronary veins, and contribute to the physiological 
regulation of vascular tone and blood flow. KATP channels are expressed also in the vascular 
endothelium (Yoshida et al. 2004) and may modulate vasodilatation in response to shear stress and 
pathophysiological conditions, such as hypoxia, ischemia, acidosis and septic shock as well as some 
vasodilators, e.g. adenosine (Yoshida et al. 2004; Adebiyi et al. 2008). 
2.3 Acute Heart Failure Syndromes 
2.3.1 Pathophysiology and risk markers of AHF 
Multiple reasons are involved in the pathogenesis of AHF, starting from nonadherence to diet, 
pharmacologic therapy or fluid restriction and ending in cardiogenic shock and multiorgan failure. 
However, fluid accumulation is the most important factor causing hospitalization of patients with 
AHF and traditionally it has been considered simply as the major cause of the syndromes (Metra et 
al. 2008a). This opinion has now been challenged. Most patients with AHF can be divided into two 
main types according to their symptoms, especially according to their blood pressure (Gheorghiade 
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et al. 2005a). Furthermore, Cotter et al (Cotter et al. 2008) proposed that the mechanisms behind 
AHF are more complex than simply fluid accumulation. They distinguished two categories of 
symptoms of ADHF. Usually ADHF is the end result of a relatively slow (days to weeks) 
deterioration of severe chronic HF. However, it can be a rapidly progressive disorder of high blood 
pressure (BP) seen in the emergency rooms, accompanied by severe acute dyspnoea.  Moreover, 
ADHF may be the result of the decrease in myocardial contractility due to ischemia. On the other 
hand, it can be caused by a combination of increased vascular resistance with decreased cardiac 
contractility, even though EF is relatively well preserved. This leads to severe hypertension with 
increased diastolic left ventricular failure (Cotter et al. 2008). 
Volume overload is typical for AHF and is traditionally believed to be the main cause of congestion. 
Thus, treatment with diuretics results in recovery of the fluid homeostasis. However, recent studies 
do not necessarily support this concept. The symptoms of HF e.g. fatigue and increased shortness of 
breath as well as an increase in pulmonary pressure have been shown to occur days to weeks before 
any weight gain was first observed (Cotter et al. 2008). Furthermore, there is evidence that even a 
dramatic rise in cardiac filling pressure (preceding an AHF hospitalization) often occurs without any 
significant change in weight gain in patients with chronical hemodynamic monitoring devices 
(Cotter et al. 2008). In addition, even treatment with a high dose diuretic has not been associated 
with improved outcome (Cotter et al. 1997). In fact, a high dose of loop diuretics has been 
associated with a higher risk of renal failure (Butler et al. 2004). 
Myocardial ischaemia is considered as an important trigger of AHF and more than a half of the  
patients hospitalized with AHF have a history of chronic ischemic heart disease in the USA, in 
Europe as well as in Finland (Siirila-Waris et al. 2006; Alla et al. 2007). Furthermore, Gheorghiade 
et al (2005) in PRESERVD-HF study (Gheorghiade et al. 2005b) studied 51 patients with AHF 
who were admitted with worsening HF and a history of CAD but not with an acute coronary event. 
Most of the patients had detectable levels of cardiac troponin (cTn) already at the initial 
measurement, and some patients displayed cTn release during hospitalization. The release of  cTn is 
thought to be a marker for myocardial injury, and therefore the study raised the possibility that 
injury occurred in most patients admitted with AHF.  
According to FINN-AKVA, elevated cTn levels are common in AHF patients without ACS, cTnI 
being more often elevated than cTnT. Increase in both cTnI and cTnT correlated with increased 
mortality. However, they did not act as independent risk markers (Ilva et al. 2008). Cystatin C is a 
novel marker of renal function, which has been discovered as a prognostic marker in AHF. 
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According to FINN-AKVA, cystatin C was a strong and independent predictor of outcome at 12 
months in AHF. In spite of normal plasma creatinine, cystatin C identifies patients with poor 
prognosis (Lassus et al. 2007). 
Arrhythmias are common in chronic heart failure. In congestive heart failure (CHF), atrial 
fibrillation (AF) is accompanied by a marked attenuation of the cardiac sympathetic response to 
acute hemodynamic stress in isometric exercise (Gould et al. 2008). Previously, impairment of the 
baroreceptor responses has been associated with abnormal hemodynamic responses to isometric 
exercise (Fukuma et al. 2004). This indicates that AF could be associated with the impairment of the 
baroreceptor response in CHF. According to the EuroHeart Failure Survey II (EHFS II) (Nieminen 
et al. 2006), 38.7%  of the patients had AF. However, the role of new arrhythmias in acute heart 
failure is largely unknown. Nevertheless, AF has been shown to be a strong predictor of the 
reappearance of symptoms and death in patients admitted for AHF (Benza et al. 2004). 
Rupture of chordae tendineae or a papillary muscle can lead to acute mitral regurgitation, which in 
turn, may be a cause of acute pulmonary edema and a rapid decrease in myocardial contractility, 
leading further to AHF. Instead, the role of chronic ischemic mitral regurgitation as a cause for AHF 
is less clear. However, major increases in mitral regurgitation and systolic pulmonary-artery 
pressure during exercise have been observed a few days after acute pulmonary edema (Pierard and 
Lancellotti 2004). This suggests that acute pulmonary edema is associated with the dynamic 
changes in ischemic mitral regurgitation and the further development of AHF. 
Recent studies have revealed that elevated BP plays a central role in the pathogenesis of AHF in 
most patients. Initial BP measurements in the emergency room before any treatment has shown that 
BP is elevated prominently at the onset of AHF (Milo-Cotter et al. 2007). A marked increase in 
systemic vascular resistance (SVR) may also be an important trigger for AHF. The extreme 
vasoconstriction combined with impaired cardiac power (CP), defined as the product of CO and 
systemic arterial pressure, induces a vicious cycle of afterload mismatch leading to a reduction of 
CO and elevated left ventricular end-diastolic pressure. This affects the pulmonary capillaries 
resulting in pulmonary edema. However, the basic reason for the increase in SVR is still unknown. 
Increased arterial stiffness could be one reason for the increased SVR in AHF, since the incidence 
of both AHF and arterial stiffness increases with age (Redfield et al. 2005). 
Diastolic heart failure (DHF) is defined as heart failure with preserved systolic function 
accompanied with other signs of heart failure. DHF is diagnosed by echocardiography as the normal 
ejection fraction (EF >40-45%) combined with diastolic dysfunction. Preserved EF is detected in 
21
24% to 55% of HF patients depending on the study population (Gorelik et al. 2009). DHF patients 
are usually older females. They are more often hypertensive, obese, and suffering from chronic 
obstructive pulmonary disease or atrial fibrillation, but not from coronary artery disease. They may 
well receive calcium antagonists, but are less likely to be treated with ACEIs or digoxin (Gorelik et 
al. 2009). A study on patients with hypertensive pulmonary edema has shown that EF during an 
episode of acute hypertensive pulmonary edema is similar to that measured after the treatment of the 
hypertension. (Gandhi et al. 2001). Thus, a normal EF after the BP has been controlled, indicates 
with high probability that the pulmonary congestion was due diastolic dysfunction. However, in 
patients with AHF, echocardiographic EF may correlate poorly with hemodynamic measures of the 
left ventricular contractility and outcome (Uriel et al. 2005). One possibility is that heart failure in 
patients with diastolic dysfunction might be paroxysmal rather than chronic (Banerjee et al. 2004). 
Thus, an acute worsening of diastolic function may be one of the main echocardiographic findings 
in patients with AHF, present predominantly in emergency units. 
Chronic renal dysfunction is one of the strongest risk factors for mortality in patients with chronic 
HF. In this respect, renal function is considered as useful indicator for heart failure prognosis. 
Worsening of renal function has been diagnosed also in patients hospitalised for AHF (Metra et al. 
2008b) and it may be a marker of the disease severity. The best single predictor for mortality in 
AHF patients admitted to hospital according to ADHERE registry in the United States was the 
presence of concomitant high admission levels of blood urea nitrogen followed by low admission 
systolic blood pressure and then by high levels of serum creatinine (Fonarow et al. 2005).  
Activation of neurohormonal pathways and inflammatory cascades has been known to contribute to 
the chronic HF for a long time. The participation of neurohormones and inflammation in AHF is 
more complex and has been less extensively studied. However, it has been shown that the levels of 
both neurohormones and inflammatory markers increase during the acute phase of AHF (Milo et al. 
2003). In addition, a high lymphocyte ratio has been observed to be related to high BP (Cotter et al. 
2008). A low lymphocyte ratio, on the other hand, was related to higher troponin and more severe 
recurrent HF and death (Cotter et al. 2008). The parallel increase in systolic BP and lymphocytes 
supports the idea that there is an interaction between inflammatory activation and increased arterial 
stiffness, further evidence for a link between inflammatory and hemodynamic events in AHF 
(Vlachopoulos et al. 2005). 
The Cardiac Resynchronization-Heart Failure (CARE-HF) trial (Cleland et al. 2001) showed that 
patients with chronic heart failure and cardiac dyssynchrony benefitted from cardiac 
resynchronization therapy (CRT). Not only were the cardiac function and symptoms improved and 
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the hospitalization and complications reduced, but also the mortality was reduced (Cleland et al. 
2005). In addition, a recent study utilizing exercise Doppler echocardiography, showed that the 
response to CRT largely depended on the presence of contractile reserve collaterally with the extent 
of LV dyssynchrony and the severity of mitral regurgitation (Moonen et al. 2008). However, the 
importance of  dyssynchrony in AHF is obscure. The only study on dyssynchrony in AHF, showed 
that the intraventricular conduction delay was associated with more adverse outcome in patients 
admitted with AHF (Brophy et al. 1994). Subsequently, a multicenter, international, observational 
study, Karolinska-Rennes (KaRen), has been designed to characterize electrical and mechanical 
dyssynchrony and to assess its prognostic impact in patients presenting acute heart failure with 
preserved ejection fraction (Donal et al. 2009). 
2.3.2 Current pharmacological management of AHF 
Diverse pharmacological agents are used in the treatment of AHF. Nevertheless, there is sparse data 
from clinical trials, mostly done with heterogenous patient populations without appropriate 
randomization. These trials have shown improvements in hemodynamics, but none of the agents 
used have reduced mortality. The multiple mechanism of action of the drugs in use are listed in  
table 1. 
Opiates
Traditionally morphine has been used in the treatment of acute pulmonary oedema and it is still in 
practise for relieving the symptoms of AHF. ESC guidelines states that morphine should be 
considered in the early stage of the treatment of patients with severe AHF, particularly in patients 
with restlessness, anxiety, or chest pain (Dickstein et al. 2008). However, morphine can cause many 
adverse side-effects, including depressed respiration, which need to be monitored. 
Diuretics 
Administration of diuretics is an effective treatment for symptoms secondary to congestion and 
volume overload and is recommended for the sodium and water retention in AHF. The loop 
diuretics are the most effective and most frequently used diuretics in treating of AHF (Somberg and 
Molnar 2009) and are therefore recommended either alone or in combination with a vasodilator as 
initial therapy in patients with volume overload (Amin 2008). Furosemide, in turn, is the most often 
used loop diuretic. Before the increase in urinary sodium and water output, i.v. furosemide provides 
rapid symptomatic relief. This beneficial effect is due to the dilatation of peripheral capacitance 
vessels, consequently there is a decrease in left ventricular filling pressure and immediate relief of 
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the symptoms of pulmonary congestion (Jhund et al. 2000; Somberg and Molnar 2009). Plasma 
vasopressin concentrations are elevated in patients with worsening heart failure due to fluid 
overload  and LV systolic dysfunction. This may lead to fluid retention and hemodynamic 
abnormalities. Vasopressin antagonists, which are able to treat congestion without causing 
electrolyte abnormalities or worsening renal function, can relieve the symptoms in AHF. Tolvaptan
is one of the most extensively investigated  oral vasopressin V2-receptor antagonist that decreases 
body weight and increases urine volume without inducing renal dysfunction or hypokalemia 
(Gheorghiade et al. 2005c; Udelson et al. 2008). 
Vasodilators 
Intravenous vasodilators (nitrates, sodium nitroprusside and nesiritide) are used as a continuous 
infusion in the treatment of hospitalized patients during the early stages of AHF and ESC guidelines 
recommend their use for patients without symptomatic hypotension (SBP <90mmHg) or serious 
obstructive valvular disease (Dickstein et al. 2008). Nitroglycerin is most commonly used 
intravenous vasodilator in ADHF. It is predominantly a venous vasodilator compared to nesiritine, 
which dilates both venous and arterial blood vessels and has a combined diuretic and natriuretic 
effect. The most common adverse effect of nitroglycerin treatment is headache, which occurred in 
20% of the patients with ADHF in the VMAC study (VMAC 2002). This was followed by 
asymptomatic hypotension (8%) and nausea (6%) and there were also some cases of symptomatic 
hypotension (Elkayam et al. 2008). Nesiritide is a recombinant 32 amino acid human B-type 
natriuretic peptide (hBNP) and therefore chemically and structurally identical to the endogenous 
hormone. It was introduced into clinical practice in the USA in 2001. Nesiritide increases cytosolic 
cGMP levels by binding to NP receptors. It has venous and arterial vasodilatory effects that reduce 
preload and afterload, and induces coronary vasodilatation. In addition, nesiritide increases cardiac 
output without having any direct inotropic effects. The use of nesiritide is normally restricted to 
patients hospitalized with acutely decompensated heart failure and who have dyspnea at rest 
(Colucci 2001; Maisel et al. 2008). 
Inotropic agents 
The infusion rate of the inotropic drugs needs to be modified according to symptoms. Also blood 
pressure should be continuously monitored. Furthermore, weaning patients from the drug infusion 
needs to be done carefully. Dobutamine is a positive inotropic agent, acting via stimulation of the 
1-ARs. It causes dose-dependent positive inotropic and chronotropic effects, starting rapidly after 
the beginning of the i.v. infusion. Dopamine also stimulates 1-ARs, both directly and indirectly and 
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is used as an additional inotropic agent. PDEIs inhibit the breakdown of cyclic AMP causing 
inotropic and peripheral vasodilating effects. Milrinone and enoximone are two PDEIs widely used 
in clinical practice. They are administered by continuous infusion, evoking an increase in cardiac 
output and stroke volume, and a simultaneous decrease in pulmonary artery and wedge pressures as 
well as pulmonary vascular resistance (Dickstein et al. 2008). Compared to beta-agonists, PDEIs 
preserve hemodynamic effects fully during complete beta-blockade, since their site of action is 
beyond the beta-adrenergic receptor. Thus, PDEIs have been recommended for inotrope-requiring 
patients with decompensated heart failure who are undergoing long-term beta-blocking therapy, 
where a beta-agonist such as dobutamine would be less effective (Bristow et al. 2001). Cardiac 
glycosides produce a small increase in CO and a reduction of filling pressure. According to ESC 
guidelines, in AHF, cardiac glycosides like digitalis, may be useful in slowing the vetricular rate in 
rapid AF (Dickstein et al. 2008). However, a meta-analysis of digitalis studies has revealed that 
there is no evidence for any benefits in terms of mortality between treatment and control groups. 
Nonetheless, digitalis therapy lowered the rate of both hospitalization and clinical decline (Hood et 
al. 2004). Levosimendan is an inodilator compound, having both inotropic and vasodilatory effects. 
It belongs to the group of calcium sensitizers and its clinical use is discussed in detail in chapter 2.4. 
Vasopressors 
Norepinephrine, the recommended vasopressor in cardiogenic shock, is not a first-line agent and it 
should be used only if other inotropic agents and fluids do not restore the systolic blood pressure. In 
addition, sepsis patients with AHF may need vasopressor therapy. Norepinephrine can be used with 
other inotropic agents, but must be withdrawn as soon as possible. Epinephrine is not recommended 
as vasopressor or inotropic agent in cardiogenic shock. Its use should be limited to rescue therapy in 
cardiac arrest (Dickstein et al. 2008). 
Renin angiotensin aldosterone system (RAAS) inhibitors and -blockers
Beta-blockers, ACEIs, ARBs as well as aldosterone antagonists have been success stories in drug 
development for chronic HF. However, there is no consensus about the advantages of ACEI/ARB 
therapy in AHF. In general, the ESC guideline recommends that treatment with these agents should 
be initiated before discharge from hospital (Dickstein et al. 2008). In particular, in patients at high 
risk for development chronic HF, ACEIs and ARBs have an important role in the early management 
of AHF and acute MI (Dickstein et al. 2008). These agents attenuate remodelling and reduce 
morbidity and mortality. Patients on ACEI/ARB therapy admitted with worsening HF should have 
treatment continued with the highest tolerated dose whenever possible (Dickstein et al. 2008). 
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In patients admitted with acutely decompensated HF, the dose of -blockers may need to be reduced 
temporarily. In general, treatment should not be stopped, unless the patient is clinically unstable 
with signs of low output. In patients admitted with de novo AHF, -blockers should be considered 
when the patient has become stabilized on an ACEI or ARB and treatment with the -blocker 
preferably initiated before hospital discharge (Dickstein et al. 2008). Data from the Italian survey on 
acute heart failure, established that in patients hospitalized for worsening HF, non-use or 
discontinuation of -blockers was associated with a significant higher mortality (Orso et al. 2009).
Furthermore, intravenous -blockers are not contraindicated in patients with AHF who present with 
hypertension and/or atrial fibrillation with a rapid ventricular response (Khan et al. 2008). 
Cardioselective (1-selective) -blockers are usually used in HF patients, because many of the side-
effects of the non-selective blockers i.e. bronchospasm, peripheral vasoconstriction, alteration of 
glucose and lipid metabolism of these drugs are attributable to their blockade of 2-receptors. 
Therefore, -blockers that selectively block 1-receptors are thought to produce fewer adverse side-
effects than those drugs that non-selectively block both 1- and 2-receptors.
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Table 1. Pharmacological management of Acute Heart Failure Syndromes
Category Agents Mechanism of action Indication Major adverse side-effecs 
Morphine and its 
analogues 
Morphine μ1 and μ2 opioid receptor 
agonism 
Restlessness, anxiety, 
chest pain 
Depression of respiration, 
nausea 
Loop diuretics Furosemide 
Bumetadide 
Torasemide 
Inhibition of the Na-K-Cl 
cotransporter-2 (NKCC2) 
Volume overload, 
congestion 
Hypovolemia, hypokalemia, 
hyponatremia, neurohumoral 
activation, hypotension 
following initiation of 
ACEI/ARB therapy 
Vasopressin 
antagonists 
Tolvaptan 
Conivaptan 
Arginine vasopressin receptor 2 
(V2) antagonism 
V1- and V2- receptor 
antagonism 
Volume overload, 
congestion 
Vasodilators Nitroglycerin 
Sodium 
nitroprusside 
Formation of NO (effect via 
soluble GC) 
Pulmonary congestion, 
edema 
Hypotension, headache 
Hypotension, cyanide 
toxicity 
Natriuretic peptides Nesiritide NPR1 (membrane-bound GC) 
and NPR3 receptor agonism 
Pulmonary congestion, 
edema 
Hypotension 
Beta-agonists Dobutamine 
Dopamine 
Adrenergic 1-receptor 
agonism 
Dopamine D1- and adrenergic 
1- and 1-receptor agonism 
Need of inotropic support, 
low CO, hypotension 
Tachycardia, arrhythmias 
Tachycardia, arrhythmias, 
vasoconstriction 
Phosphodiesterase 
inhibitors 
Milrinone 
Enoximone 
Inhibition of the PDE3 and 
PDE4
Need for inotropic 
support, low CO 
Arrhythmias, increase in 
mortality 
Vasopressors Noradrenaline 
Adrenaline 
Adrenergic 1-, 1- and 2-
receptor agonism 
Adrenergic 1-, 2-, 1- and 2-
receptor agonism 
Cardiogenic shock 
Rescue therapy in cardiac 
arrest 
Increase in systemic vascular 
resistance 
Cardiac glycosides Digoxin Inhibition of the Na+/K+ -
ATPase 
Rapid AF Arrhythmias, paroxysmal 
atrial tachycardia with A-V 
block (digoxin toxicity) 
Calcium sensitizers Levosimendan Improvement of Ca2+ binding 
to troponin C, opening of the  
KATP channels and inhibition of 
PDE3
Need for inotropic 
support, low CO, signs of 
organ hypoperfusion 
Hypotension 
Chronical treatment Objective 
Beta blockers Nebivolol  
Bisoprolol 
Metoprolol 
Carvedilol 
Adrenergic 1-receptor 
antagonism 
Adrenergic 1- and 1-receptor 
antagonism 
Attenuation of 
remodelling and reduction 
of morbidity and mortality 
Bradycardia, hypotension, 
worsening of asthma 
Orthostatic hypotension, 
edema 
Angiotensin 
converting enzyme 
inhibitors 
Captopril 
Enalapril 
Lisinopril 
Ramipril 
Trandolapril 
Inhibition of the conversion of 
Ang I to Ang II  
Attenuation of 
remodelling and reduction 
of morbidity and mortality 
Cough, hyperkalemia, 
hypotension, dizziness 
Angiotensin 
receptor antagonists 
Candesartan 
Valsartan 
Ang II receptor type 1 (AT1)
antagonism 
Attenuation of 
remodelling and reduction 
of morbidity and mortality 
Headache, dizziness 
Aldosterone 
antagonists 
Eplerenone 
Spironolactone 
Mineralocorticoid receptor 
antagonism 
Attenuation of 
remodelling and reduction 
of morbidity and mortality 
Hyperkalemia, hypotension, 
dizziness 
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2.3.3 Unmet needs for the treatment of AHF 
Undoubtedly, therapy for AHF should improve symptoms and hemodynamics of acutely 
hospitalized patients without adverse effects and the risk of mortality. However, patients with AHF 
have usually been diagnosed with other cardiac and also noncardiac contributing disorders, such as 
coronary artery disease, chronic ischemic heart disease, hypertension, atrial fibrillation, type 2 
diabetes mellitus. In severe types of the syndrome, there may be cardiorenal or multiorgan failure 
which needs to be taken into account in the choice of appropriate medication. Ideal medical 
treatment should prevent myocardial damage, modulate neurohumoral and inflammatory activation, 
and preserve or even improve renal function (Figure 2.). Moreover, costs of index hospitalization 
increase depending on the severity of the different classes AHF (Harjola et al. 2009). This has 
created a growing need for effective treatment for the most severe classes of the syndrome. 
There is a vigorous debate of the role of inotropic therapy in the management of AHF and 
counterarguments have been postulated (Petersen and Felker 2008). Nevertheless, the use of 
conventional inotropic agents has been shown to have favourable haemodynamic effects in patients 
with decreased cardiac contractility. According to Acute Decompensated Heart Failure National 
(ADHERE) Registry, 9.6% of patients hospitalized for AHF in the United States receive 
intravenous inotrope therapy, either PDEIs or beta1-adrenergic agonists (1-AR agonists) (Abraham 
et al. 2005). These patients tended to have a clinical profile associated with more severe disease, 
including lower blood pressure, lower ejection fraction, and higher blood urea nitrogen. The use of 
PDEIs and 1-AR agonists in heart failure has consistently been associated with increased 
myocardial oxygen demand, more cardiac arrhythmias, and worsened mortality in many clinical 
trials. This unsatisfactory outcome is believed to be related to the fact that these agents increase 
myocardial concentrations of cAMP, leading to an increase in the level of intracellular calcium 
which in turn can trigger myocardial cell death and provoke lethal arrhythmias. Furthermore, 
according to FINN-AKVA, the mortality increased in proportion to the number of inotropes used 
(Rossinen et al. 2008). The administration of inotropes was related to low BP, low ejection fraction, 
elevated C-reactive protein and cardiac markers and was a marker of increased mortality in patients 
with AHF. However, the use of a single inotrope during hospitalization appeared to be rather safe 
(Rossinen et al. 2008).
For these reasons, there is a clear need for improvements in therapy. Some new drugs have been 
recently introduced for the treatment of AHF. One of them is istaroxime, a new agent with inotropic 
and especially powerful lusitropic properties, that is improvement in relaxation. It inhibits the 
sodium–potassium ATPase (Na+-K+ pump) and stimulates the sarcoplasmic reticulum calcium 
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ATPase isoform 2 (SERCA-2) and is consequently believed to improve contractility as well as
causing diastolic relaxation (Khan et al. 2009). Data from human phase II study (HORIZON-HF) 
indicated that istaroxime decreases PCWP and possibly improves diastolic function without evoking 
any significant change in heart rate (HR), blood pressure, ischemic or arrhythmic events (Blair et al. 
2008; Gheorghiade et al. 2008). However, the mechanism of action of istaroxime means that it can 
contribute to an increase in cytosolic calcium [Ca2+]i in a manner similar to the cardiac glycosides, 
and to this extent, harmful effects attributable to increased [Ca2+]i cannot be excluded. In addition, 
the enhanced calcium uptake in the SR causes a greater amount of calcium release in every diastole-
systole cycle. Cardiac-specific myosin ATPase activators are another novel class of agents designed 
to improve myocardial contractility. They accelerate the productive phosphate-release step of the 
crossbridge cycle (Bragadeesh et al. 2007). CK-1827452 is a new agent that directly activates 
myosin, prolonging the duration of time that myosin remains in a force-generating reaction with 
actin and enhancing the extent of myocyte shortening, with no effect on the Ca2+ transient (Solaro 
2009).
Calcium sensitization is a mechanism that is thought to resolve many of the disadvantages of the 
therapies that increase the cytosolic calcium concentration [Ca2+]i. Calcium sensitizers do not 
increase the energy required for Ca2+ handling and are able to reverse contractile dysfunction under 
pathophysiological conditions. However, calcium sensitizers carry a potential risk of the diastolic 
dysfunction due to the impaired relaxation, which will reduce the rate of ventricular filling (Endoh 
2008). A set of compounds has been under development as calcium sensitizers during the past two 
decades. Most of them have a combination of mechanism of action of calcium sensitization and 
PDE3 inhibition. Some of them have only weak PDE3 inhibitory effect like EMD 57033, MCI-154, 
Org 30029 and SCH00013, but also pure calcium sensitizers, like CGP 48506, have been developed 
(Endoh 2002; Kass and Solaro 2006). However, none of them have been a success story in the 
clinic. Pimobendan is a calcium sensitizer with potent PDE3 inhibitory properties in the same 
concentration range (Endoh 2002). It is approved in HF patients in Japan only (Kass and Solaro 
2006). However, pimobendan has been used in the clinical management of CHF secondary to both 
dilated cardiomyopathy (DCM) and chronic degenerative valvular disease in dogs (Gordon et al. 
2006).
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Figure 2. The vicious cycle of heart failure. Renin angiotensin aldosterone system (RAAS); Sympathetic nervous 
system (SNS). 
2.4 Levosimendan 
2.4.1 Physicochemical properties
Levosimendan is commercially available as a powder, to be dissolved in a solution of glucose 5% in 
water and administered as an intravenous infusion. The chemical name of levosimendan is (-) (R)-
[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3- pyridazinyl) phenyl] hydrazono] propanedinitrile (WHO 
Drug Information Vol. 7, No. 3, 1993). Its molecular weight is 280.291 and the molecular formula 
C14H12N6O (Figure 4). Levosimendan, is a weak acid and a moderately lipophilic compound with a 
pKa value of 6.2. 
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Figure 4. The molecular formula of levosimendan.
2.4.2 Pharmacokinetics
The molecule has a short elimination half-life of approximately 1 h, and is 95– 98% bound to 
plasma proteins. The drug is mostly metabolized through glutathione conjugation at one of its nitrile 
groups followed by amino acid cleavage and cyclization or acetylation (Lehtonen et al. 2004; 
Koskinen et al. 2008). Even though it is administered intravenously, levosimendan is excreted into 
the small intestine and reduced by intestinal bacteria to an amino phenolpyridazinone metabolite 
(OR-1855), which is further metabolised by acetylation to N-acetylated conjugate (OR-1896). The 
circulating metabolites OR-1855 and OR-1896 are formed slowly, and their maximum 
concentrations are seen on average 2 days after cessation of  a 24 h infusion. The haemodynamic 
effects after levosimendan infusion appear to be similar between fast and slow acetylators. OR-
1896, an active metabolite, is approximately 40% bound to plasma proteins. It has a longer half life 
(75 to 80 h) than levosimendan and it is responsible for the prolonged hemodynamic effects, which 
can be detected for 7–9 days after a 24 h continuous infusion of levosimendan (Antila et al. 2007; 
Puttonen et al. 2007). The hemodynamic effects after levosimendan infusion are thus, combination 
of the acute effects by levosimendan itself and the long lasting effects by OR-1896. 
2.4.3 Mechanism of action
2.4.3.1 Positive inotropic effect 
Since it is a calcium sensitizer, levosimendan does not increase [Ca2+]i. It rather increases 
myofilament calcium sensitivity by binding to cTnC in a calcium-dependent manner. Levosimendan 
binds to the calcium-saturated N-terminal domain of troponin C and stabilizes the troponin molecule 
with subsequent prolongation of its effect on the contractile proteins (Pollesello et al. 1994). The 
heart contracts when calcium binds to cTnC and it relaxes when calcium dissociates from cTnC. 
Therefore, the calcium saturated form of cTnC is an ideal target for calcium sensitisers (Haikala and 
Linden 1995). Furthermore, a desirable feature of a calcium sensitizer is that it should not impair the 
relaxation of cardiac muscle, i.e. it must detach from cTnC when Ca2+ dissociates. In fact, 
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levosimendan behaves in this way (Figure 5.) (Pollesello et al. 1994; Levijoki et al. 2000; Sorsa et 
al. 2004; Antoniades et al. 2007).  In addition, levosimendan has been shown to actually enhance 
diastolic function in pacing induced heart failure dogs during exercise (Tachibana et al. 2005). It is 
also essential that an efficacious calcium sensitizer must not prevent or inhibit any of the protein–
protein interactions required for muscle contraction and relaxation, and furthermore, it should not 
exert any detrimental actions on troponin’s functions, levosimendan does not (Sorsa et al. 2004).
2.4.3.2 Stereoselective interaction with cardiac troponin C 
Levosimendan has a chiral carbon atom in its pyridazine ring (Figure 4.). Therefore, it has an optical 
stereoisomer, dextrosimendan . Levosimendan and dextrosimendan are the (R)-(-) and (S)-(+) 
enantiomers of simendan. The interaction of simendan stereoisomers on cTnC has been shown to be 
different in the absence of cardiac troponin I (cTnI) (Sorsa et al. 2004). Both stereoisomers 
interacted with both, C- and N-domains of the isolated cTnC. However, levosimendan has been 
shown to have an order of magnitude higher affinity for the N-domain than dextrosimendan (Sorsa 
et al. 2004). The binding of calcium ion to the N-domain of cTnC appropriately initiates the 
contraction of the cardiac muscle, and thus, explains the stereospecific mode of action of the 
simendans in cardiac preparations. 
The positive inotropic effect of levosimendan has been demonstrated in many in vitro experiments. 
Levosimendan has been shown to increase cardiac contractility in isolated cardiomyocytes, papillary 
muscles, atrial muscle strips, ventricular muscle strips, and in isolated hearts (Haikala et al. 1995; 
Lancaster and Cook 1997; Hasenfuss et al. 1998; Janssen et al. 2000). In in-vivo experimental 
models, levosimendan has shown positive inotropic effects in normal rats, dogs, cats and rabbits. In 
addition, levosimendan has been proven to be even more potent in animal model of heart failure 
(Levijoki et al. 2001; Louhelainen et al. 2007; Masutani et al. 2008). 
One plasma metabolite of levosimendan which possesses biological activity, OR-1896, is also a 
potent positive inotropic compound. In anaesthetised dogs, the overall cardiovascular 
pharmacodynamic profile of OR-1896 was shown to be rather similar to that of levosimendan 
(Banfor et al. 2008). Levosimendan and OR-1896 were intravenously infused at 30 min intervals in 
cumulatively increasing doses. They were hemodynamically active in anaesthetised dogs and 
elicited equivalent cardiovascular, whereas another metabolite, OR-1855 was inactive (Banfor et al. 
2008). In anesthetized rats, levosimendan and OR-1896 have also been shown to have similar 
hemodynamic effects (Banfor et al. 2008; Segreti et al. 2008). The relatively long-lasting duration 
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of levosimendan’s positive inotropic effect and the possible accumulation of OR-1896 after 
prolonged administration of levosimendan may modify the effects of levosimendan. 
Figure 5. Mechanism of levosimendan as an inotropic agent. (A) Levosimendan binds to troponin C during systole, 
increasing the sensitivity of myofilaments to Ca2+ levels. This phenomenon increases the contractility of myocardium 
during systole, but it does not affect diastolic function. (B) The presence of levosimendan leads to an opening of the 
active sites of troponin C, increasing in this way its sensitivity to Ca2+. Reprinted from Pharmacol Ther, 114 (2), 
Antoniades, C., D. Tousoulis, N. Koumallos, K. Marinou and C. Stefanadis, “Levosimendan: beyond its simple 
inotropic effect in heart failure”, Pages 184-97, Copyright (2007), with permission from Elsevier.
2.4.3.3 Vasodilatory effect 
Levosimendan has a pronounced vasodilatory effect. The opening of the KATP channels is believed 
to be the main mechanism of the vasodilatory effect of levosimendan. This has been shown in 
arterial and venous preparations as well as in coronary arteries. In rat mesenteric arterial myocytes, 
levosimendan hyperpolarized the cells, probably through the activation of  KATP channels, i.e. an 
effect which is known to have a vasodilating action (Yokoshiki et al. 1997). Furthermore, in the 
isolated rat small mesenteric artery preparation, levosimendan had a relaxant response in KCl 
precontracted arteries. Glibenclamide, a KATP channel blocker, inhibited the response, supporting 
33
the theory that the opening of KATP channels was the important vasodilatory mechanism. The 
response did not differ significantly between endothelium-intact and endothelium-denuded 
preparations (Ozdem et al. 2006). In isolated human portal vein, levosimendan was found to be 
about 16-fold more potent as a relaxing agent than cromakalim in noradrenaline-precontracted 
portal venous preparations. Glibenclamide totally inhibited the cromakalim-induced relaxation of 
the portal vein. However,  the effect of levosimendan was only partially prevented (Pataricza et al. 
2000), indicating that levosimendan might also have some other vasodilatory effects in addition to 
opening of the KATP channels. 
Subsequently, in isolated porcine epicardial coronary arteries, it has been shown that the specific 
BKCa channel blocker, iberiotoxin (IBTX), could suppress the maximum effect of levosimendan, 
and the KV channel blocker, 4-aminopyridine (4-AP) significantly shifted the concentration-
response curve to the right. This indicated that the vasorelaxing mechanism of levosimendan 
involves the activation of voltage-sensitive and, at large concentrations, calcium-activated 
potassium channels (Pataricza et al. 2003). However, IBTX and 4-AP were not able to suppress the 
vasodilatory effect of levosimendan in isolated rat small mesenteric arteries (Ozdem et al. 2006). In 
addition, studies with porcine coronary arteries suggest that levosimendan may also interact with 
smooth muscle EF-hand proteins, such as, calmodulin, the regulatory myosin light chains, or S100 
proteins and thus, relax coronary smooth muscle through calcium desensitization (Bowman et al. 
1999). Furthermore, the role of PDE3 inhibition cannot be excluded, since levosimendan has been 
shown to potentiate the relaxant effect of a cAMP-stimulating drug, isoprenaline in isolated porcine 
arteries (Gruhn et al. 1998). 
The vasodilatory effect of OR-1896 has been shown to be comparable to that of levosimendan in 
isolated, pressurized rat coronary and skeletal muscle arterioles. The vasodilatation was proposed to 
be mediated primarily by activation of BKCa and KATP channels, respectively (Erdei et al. 2006). In 
anaesthetised rats and dogs, the vasodilatory effect of OR-1896 is rather similar to that of 
levosimendan (Banfor et al. 2008; Segreti et al. 2008). 
Thus, it can be concluded that levosimendan predominantly stimulates KATP channels in small 
resistance vessels. In large conductance vessels, the vasodilatation may be mediated mainly through 
opening of KV as well as BKCa channels. Moreover, the duration of the vasodilatory effect is 
proportionately long-lasting, because of the formation of an active metabolite, OR-1896. 
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2.4.3.4 Anti-ischemic effect 
Endogenous protective mechanisms in heart cells, so called preconditioning, have been previously 
claimed to be mediated via KATP channels. Preconditioning is known to exist in many mammalian 
species and tissue types. It is described as a cardiac phenomenon in which a short period of ischemia 
will protect the heart from a subsequent, much longer, ischemic episode (Grover and Garlid 2000). 
The opening of the sarcolemmal KATP (sarcKATP) channels in vascular smooth muscle cell, resulting 
in membrane hyperpolarization and vasodilatation, was previously believed to be behind this 
protective mechanism. Subsequently, mitochondria KATP (mitoKATP) channels have been described 
(Liu et al. 1999; O'Rourke 2004) and the mitochondrial hypothesis has become more generally 
accepted. Furthermore, it has been shown that KATP channel openers can induce vasodilatation by 
activating two different signaling mechanisms, one pathway that is mitochondrial and another 
pathway that involves sarcKATP channel activation (Adebiyi et al. 2008). That study indicated that 
the KATP channel openers, pinacidil and diazoxide, could induce vasodilatation by two distinct 
mechanisms. The action of pinacidil required the sulfonylurea receptor (SUR 2B) whereas 
diazoxide targeted the mitochondrial electron transport chain (ETC). 
KATP openers have been shown to mimic preconditioning and the results from several studies with a 
variety of K+ channel openers have demonstrated their effects on mitochondrial function (O'Rourke 
2004). This is evidence for a link between the mitoKATP channels and protection against ischemic 
injury in intact hearts (Garlid et al. 1997) and isolated myocytes (Liu et al. 1998). The mechanisms 
believed to be behind this protective effect are prevention of mitochondrial calcium overload, 
preservation of high energy phosphates and regulation of mitochondrial volume (O'Rourke 2004). 
Mitochondrial Ca2+-activated K+ (mitoKCa) channels also exist in cardiac myocytes, and are known 
to play a key role in cardioprotection. Potassium influx through mitoKATP or mitoKCa channels 
occurs independently of each other and induces cardioprotection in a similar manner (Nishida et al. 
2009). Activation of mitoKATP channel is enhanced by protein kinase C (PKC), whereas mitoKCa
channel is activated by protein kinase A (PKA) (Nishida et al. 2009). 
Levosimendan has been demonstrated to open mitoKATP channels in liver, but also in cardiac 
preparations, indicating that it may have a cardioprotective effect. In the rat liver mitochondria, 
levosimendan at a concentration of 0.7-2.6 M could open the mitoKATP channels (Kopustinskiene 
et al. 2001). The effect was abolished by the selective mitochondrial KATP channel blocker 5-
hydroxydecanoate. In addition, levosimendan up to 2.2 M had no effect on the respiration rate of 
rat liver mitochondria. In the rat cardiac cells, levosimendan activated potassium flux to the 
mitochondrial matrix (median effective concentration, EC50, 0.83 +/- 0.24 M) (Kopustinskiene et 
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al. 2004). The anti-ischemic effect has been seen also in a dog-infarction model, where 
levosimendan (24 μg/kg bolus followed by an infusion of 0.4 μg/kg/min), when given before 
ischemia, reduced the infarct size by 50%. This reduction of infarct size was abolished by treatment 
with the KATP channel blocker glibenclamide, indicating that levosimendan had an anti-ischemic 
effect, which was mediated via opening of the KATP channels (Kersten et al. 2000). 
In addition, oral simendan (the racemate of levosimendan) has been shown to improve survival in 
rats with healed myocardial infarction during the follow-up period of 312 days. The incidences of 
mortality in control, simendan, enalapril and milrinone groups were 81%, 53%, 56% and 63%, 
respectively. The calculated mean daily dose of simendan was 2-2.5 μg/kg from the 10th week 
onwards. The mean plasma concentration of simendan was 97 ng/ml at the end of the follow-up 
period. The hemodynamic responses to simendan, measured prior to sacrifice, had been well 
preserved i.e. no tolerance developed to the hemodynamic effects of simendan (Levijoki et al. 
2001).
2.4.3.5 Antiaggregatory, anti-inflammatory and antiapoptotic effects 
Levosimendan has been shown to inhibit concentration-dependently the platelet aggregation 
induced by ADP (5 and 10 M), and collagen (2 and 5 g/mL) in human platelet-rich plasma. 
Levosimendan inhibited also the secondary wave of platelet aggregation induced by ADP, 
indicating that it may inhibit platelet signal transduction, e.g. thromboxane A2 formation (Kaptan et 
al. 2008). In vitro levosimendan was able to reverse interleukin (IL)-5-related survival of human 
eosinophils i.e. it increased the number of apoptotic eosinophils in the presence of 10 pM IL-5 with 
an EC50 value of 6.5 ± 0.7 M. The increase in the number of apoptotic cells was confirmed by the 
percentage of annexin V-positive cells, which were in the absence or presence of levosimendan (10 
M) 7 ± 1 and 86 ± 4%, respectively (Kankaanranta et al. 2007).  Moreover, levosimendan and 
dextrosimendan decreased NO production in a dose-dependent manner in macrophages and in 
fibroblasts exposed to inflammatory stimuli. They reduced IL-6 production slightly but they had no 
effect on TNF- synthesis (Sareila et al. 2008). 
2.4.4 Effects in combined heart and renal failure model 
When administered via the drinking water, levosimendan dose-dependently prevented 
cardiomyocyte apoptosis and normalized salt-induced increased expression of natriuretic peptide, 
and decreased urinary noradrenaline excretion in salt-sensitive hypertensive Dahl/Rapp rats 
(Louhelainen et al. 2007). Preventative treatment with levosimendan for seven weeks in rats fed a 
high-salt diet, improved also survival, increased cardiac function, and ameliorated cardiac 
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hypertrophy. In addition, levosimendan also corrected salt-induced declines in myocardial 
SERCA2a protein expression and myocardial SERCA2a/NCX-ratio. In conclusion, the modulation 
of pro-inflammatory and pro-apoptotic pathways by levosimendan may be part of its beneficial 
effects in the progression of decompensated heart failure. 
2.4.5 Effects in stroke models 
In addition to the above mentioned studies, there is strong experimental evidence that levosimendan 
may have preventive effects on stroke. Recent unpublished studies in experimental models of 
primary and secondary prevention of stroke, confirmed by using MRI and/or histology, have 
demonstrated this effect. Oral treatment with levosimendan prevented strokes and mortality in Dahl 
salt-sensitive and stroke-prone spontaneously hypertensive rats. The effects were seen at low daily 
doses of levosimendan alone and in combination with the angiotensin II receptor blocker, valsartan. 
An international patent for a combination treatment with levosimendan and ACE inhibitor or AngII 
receptor blocker has been accepted and published (Sallinen et al. 2009). 
2.5 Clinical use of levosimendan 
Levosimendan is the only calcium sensitizer, which is widely used in the clinical management in 
humans. Today it has an established place in the treatment of AHF. Levosimendan increases 
myofilament calcium sensitivity and has a highly selective PDE3 inhibitory action. It has been 
shown to enhance cardiac contraction without increasing oxygen consumption, and thus, having an 
energetically advantageous effect on the contraction (Ukkonen et al. 1997; Ukkonen et al. 2000). 
Levosimendan induces vasodilatation by opening the sarcolemmal KATP channels in the resistance 
arteries. There is some evidence that it may be also a venodilator and therefore, reduce the central
venous pressure and improve the pulmonary congestion, and this may be the mechanism behind the 
observed improvement in renal function (Yilmaz et al. 2007). Moreover, levosimendan-evoked 
mitochondrial KATP channel opening may have cardioprotective effects due to the ATP synthesis 
during ischemia. In summary, the positive effects on the energy balance could be of major 
significance in the use of levosimendan in the treatment of AHF (Nieminen et al. 2009). 
2.5.1 Use in acute heart failure 
To date, levosimendan has been approved in 47 countries worldwide for short-term treatment of 
AHF. According to ESC guidelines, levosimendan infusion is recommended in acutely 
decompensated heart failure and may be effective in patients with decompensated chronic HF, too 
(Dickstein et al. 2008). The effects of levosimendan on the symptoms of AHF have been evaluated 
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in several clinical trials. The effects on overall hemodynamics in different trials are presented in 
table 3. Some of these trials have suggested that levosimendan might improve prognosis and 
mortality in patients with decompensated heart failure. There are three trials, LIDO, RUSSLAN and 
CASINO, which were carried out in patients with high filling pressures, where intravenous 
levosimendan was compared with placebo or dobutamine. The mortality rate of levosimendan was 
statistically significantly lower in the levosimendan group than in the dobutamine group (LIDO) or 
placebo group (RUSSLAN) or in both (CASINO) (Follath et al. 2002; 2002; Cleland et al. 2004; 
Lehtonen 2004; Lehtonen and Poder 2007). However, two larger trials (SURVIVE and REVIVE II) 
in patients who were hospitalized for worsening of heart failure, but in whom it was not essential to 
measure the filling pressure, indicated that though levosimendan did improve the symptoms of HF, 
it did not improve survival (Cleland et al. 2006; Lehtonen and Poder 2007; Mebazaa et al. 2007) 
(Table 2.). Nevertheless, levosimendan proved beneficial compared to dobutamine in specific 
subgroups of patients in the SURVIVE trial. Levosimendan treatment lowered all-cause mortality 
during the first weeks following treatment, in patients admitted with acute decompensated heart 
failure and with a known history of CHF and/or currently treated with oral -blockers (Mebazaa et 
al. 2009).
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2.5.2 Additional clinical use 
In addition to its use in ADHF, as recommended according to ESC guidelines, levosimendan has 
found increasing off-label use also for other cardiovascular symptoms in acute cardiovascular 
events and in intensive care units. Ischemic heart disease and septic shock as well as perioperative 
cardiac support are conditions where the use of levosimendan has been shown to have beneficial 
clinical effects. 
2.5.2.1 Ischemic heart disease and cardiogenic shock 
Cardiogenic shock (CS) is the leading cause of death in patients hospitalized for acute myocardial 
infarction (AMI) (Hochman et al. 2000). The syndrome has been defined as the inability of the 
heart, with its impairment of pumping function, to deliver sufficient blood flow to the tissues to 
meet resting metabolic demands (Califf and Bengtson 1994). The symptoms of CS are diagnosed as 
the combination of low mean arterial blood pressure, low cardiac index (CI), elevated PCWP, and 
an increase in systemic vascular resistance index (Hochman et al. 2000). Moreover, there is 
believed to be a systemic inflammatory response owing to the release of inflammatory cytokines 
and the expression of inducible nitric oxide synthase and extraneous vasodilatation may also play an 
important role (Kohsaka et al. 2005). Furthermore, patients with large MIs often have signs of 
inflammation like elevation of body temperature, white blood cell count, complement, interleukins, 
C-reactive protein, and other inflammatory markers (Hochman 2003) (Figure 3.). Early 
revascularization, either by percutaneous coronary intervention (PCI) or coronary artery bypass 
graft (CABG) surgery, has been shown to increase the long-term survival (Hochman et al. 2006).
Levosimendan infusion was shown to improve hemodynamics in critically ill patients with CS 
requiring catecholamine therapy (Delle Karth et al. 2003). In patients with AMI complicated by 
severe and refractory CS, therapy with levosimendan added to current therapy resulted in a better 
outcome and may have contributed to improved survival compared with phosphodiesterase 
inhibitor, enoximone (Fuhrmann et al. 2008). Particular, in the levosimendan-treated patients, no 
deaths because of multiorgan failure (MOF) were observed compared to mortality of 25% in the 
enoximone group. It is worth noting that in the multicenter trial SURVIVE, where levosimendan 
failed to improve mortality in acute heart failure compared with dobutamine, all patients with CS 
were excluded (Mebazaa et al. 2007). In addition, clinical data demonstrate that levosimendan does 
not increase markers of oxidative and nitrosative stress, in contrast to placebo treatment, in patients 
with advanced chronic heart failure (Parissis et al. 2008). Thus, the severity of heart failure may be 
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quite different in different patient populations and the occurrence of MOF and the systemic 
inflammatory response can be variable. Furthermore, in patients having ADHF with ischemic 
cardiomyopathy and LV ejection fraction (LVEF) <40% , left atrial functions, calculated from left 
atrial volume i.e. the active emptying fraction, the passive emptying fraction, and the reservoir 
fraction were respond better to levosimendan than to dobutamine (Duygu et al. 2008). In 
conclusion, pharmacological modulation of mitochondrial KATP channels may be beneficial in 
patients at risk of myocardial ischemia, particularly those requiring inotropic support. 
Figure 3. Shock paradigms. Classic shock paradigm is shown in black. The influence of the inflammatory response 
syndrome initiated by a large MI is illustrated in gray. Left ventricular end diastolic pressure (LVEDP); Cardiac output 
(CO); Stroke volume (SV); Systemic vascular resistance (SVR); Inducible nitric oxide synthase (iNOS): Nitric oxide 
(NO). Modified from (Hochman 2003) Circulation 107(24): 2998-3002. 
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2.5.2.2 Sepsis and septic shock 
Sepsis is referred to as a systemic disease caused by microbial invasion of normally sterile parts of 
the body. More accurately defined, sepsis is a set of non-specific inflammatory responses with 
evidence, or suspicion, of a microbial origin (Lever and Mackenzie 2007). Severe sepsis is 
accompanied by evidence of hypoperfusion or dysfunction of at least one organ system. Septic 
shock, in turn, is sepsis accompanied by hypotension or the need for vasopressors, despite adequate 
fluid resuscitation. Severe sepsis and septic shock together are some of the leading causes of death 
in noncoronary intensive care units. Increasing severity of sepsis correlates with increasing 
mortality, i.e. 25-30% for severe sepsis up to 40-70% for septic shock (Lever and Mackenzie 2007). 
Myocardial depression is related to symptoms of sepsis, although cardiac output (CO) may be 
preserved or even increased. This is explained by a maintained stroke volume due to a dilated 
ventricle and an increased heart rate (Rabuel and Mebazaa 2006). Sepsis can induce myocardial 
dysfunction which is seen in both ventricles. Echocardiography studies have noted that 40% to 50% 
of patients with prolonged septic shock have reduced ejection fraction as a sign of develop 
myocardial depression (Rudiger and Singer 2007). Alterations in sympathetic beta-adrenoceptor 
signalling are considered to impair the myocardial response to endogenous and exogenous 
catecholamines. Moreover, sepsis-induced cardiomyopathy can affect calcium homeostasis in the 
cardiomyocytes. The calcium current can be disturbed and myofilament calcium sensitivity be 
decreased (Rudiger and Singer 2007). Calcium is also related to mitochondrial dysfunction, which 
is believed to be important in the pathophysiology of sepsis, and seems to correlate to the severity 
of the disease. In brief, calcineurin (CN), activated by calmodulin-kinase (CMK), interacts with the 
mitochondrial permeability transition pore, triggering mitochondria-related death pathways 
(Rudiger and Singer 2007). Also circulatory abnormalities related to vasodilatation and vascular 
leakage are often encountered in sepsis. 
The use of levosimendan in patients with septic shock has been described in a few case reports. The 
drug was reported to improve  hemodynamics, global oxygen transport, pulmonary circulation, 
metabolism and vasopressor requirements, mostly in patients with long-lasting refractory septic 
shock (Pinto et al. 2008; Salmenpera and Eriksson 2009). Levosimendan can exert beneficial effects 
in both the left and right ventricles. As a calcium sensitizer, it does not influence the beta-
adrenoceptor signalling or evoke changes in the intracellular Ca2+ concentration. Therefore, it was 
postulated that levosimendan could theoretically be an ideal therapy for sepsis-induced myocardial 
dysfunction (Pinto et al. 2008). In addition, levosimendan enhances pulmonary and intestinal 
microcirculation a priori due to its vasodilatory actions and therefore, prevents multi-organ failure 
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(Figure 4.). Moreover, some recent experimental studies have shown that levosimendan has a 
positive effects in the rat sepsis model of cecal ligation and puncture. Treatment with levosimendan 
had a marked effect on attenuating or decreasing apoptosis and inflammation in the lung (Erbuyun 
et al. 2009). In other recent study, levosimendan equally attenuated arterial hypotension, metabolic 
acidosis and prolonged survival on mortality (Scheiermann et al. 2009). 
Figure 4. Sepsis-induced organ dysfunction. Acute respiratory distress syndrome (ARDS); Acute renal failure (ARF); 
Disseminated intravascular coagulation (DIC). Modified from (Pinto et al. 2008) Curr Opin Anaesthesiol 21(2): 168-77. 
2.5.2.3 Perioperative cardiac support 
Inotropic support is frequently required to wean patients from cardiopulmonary bypass (CBP). In 
particular, in patients with preoperative impaired ventricular function, weaning failure without 
medical or mechanical support is a common occurrence occuring in as many as 70% to 80% of 
cases (Eriksson et al. 2009). Moreover, postoperative renal dysfunction and acute renal failure are 
frequent and serious complications of cardiac surgery and these are associated with prolonged 
intensive care unit stay and hospitalization, as well as significant increases in mortality (Mangano et 
al. 1998). 
Levosimendan has been demonstrated to have beneficial effects on postoperative conditions and it 
has been postulated as a bridge therapy for the perioperative phase of cardiac surgery (Nieminen et 
al. 2009). Levosimendan has been shown to increase cardiac output without increasing myocardial 
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oxygen consumption in patients early after weaning from CPB following coronary artery bypass 
grafting (CABG) (Lilleberg et al. 1998; Nijhawan et al. 1999). Moreover, the effect of prophylactic 
levosimendan administration on weaning from and early recovery after CPB in patients with 
preoperatively impaired left ventricular function undergoing CABG was studied recently. 
Levosimendan showed a positive outcome and significantly facilitated the primary weaning from 
CPB compared with placebo (Eriksson et al. 2009). Furthermore, a comprehensive meta-analysis of 
existing trials to determine the impact of levosimendan on cardiac troponin release in patients 
undergoing cardiac surgery was done by the senior training project in Center for Overview, Meta-
analysis, and Evidence-based Medicine Training (COMET) in Milano (Zangrillo et al. 2009). The 
results suggested that the use of levosimendan was associated with a significant reduction in cardiac 
troponin I (cTnI) release in patients undergoing cardiac surgery. The authors hypothesized that the 
better preservation of early cardiac function with levosimendan may have been the result of the 
improved global tissue perfusion leading to better recovery from surgery (Zangrillo et al. 2009). 
2.5.2.4 Effects in calcium channel poisoning 
Poisoning with calcium channel blockers (CCB), accidental or intentional, has become an 
increasing caseload in the poisoning centers in recent years. This is associated with the more 
frequent use of these drugs. CCB and beta-blockers account for approximately 40% of the 
cardiovascular drug exposures reported to the American Association of Poison Centers (DeWitt and 
Waksman 2004). Verapamil causes the most severe cases and tends to produce the most 
hypotension, bradycardia, and conduction disturbances and deaths from the calcium channel 
blockers seen in emergency rooms. The adverse effects of verapamil consist of its negative effects 
on the sino-atrial and atrio-ventricular nodes reducing heart rate and atrioventricular conduction, 
reduction of  myocardial contractility by antagonism of myocardial L-type calcium channels, and 
antagonism of L-type calcium channels in vascular smooth muscle, resulting in peripheral 
vasodilatation. The toxicity of calcium channel blockers can lead also to a wide variety of 
manifestations in the central nervous system, gastrointestinal system, endocrine-metabolic, 
hematologic and respiratory systems. 
Levosimendan is believed to improve the cardiac depression and prognosis of the patients. There is 
some experimental evidence which supports these claims. In anaesthetized guinea-pigs, 
levosimendan markedly decreased mortality in the diltiazem intoxicated group (12% versus 100%) 
and in the verapamil-intoxicated group (0% versus 89%) ((Levijoki, unpublished data). However, in 
a rat model, levosimendan failed to cause any improvement in the survival time (Abraham et al. 
2009). In one other rat study, levosimendan increased CO to a similar degree as CaCl2 alone, but it 
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did not improve BP from the time of maximal toxicity. The addition of CaCl2 to levosimendan did 
not confer any further improvement in CO and BP compared to CaCl2 alone. There was either no 
mortality benefit observed with levosimendan compared to CaCl2 treated animals. However, a 
recent case report did reveal a beneficial hemodynamic effect of levosimendan in CCB overdose 
patients (Varpula et al. 2009). Clearly, more studies are needed to evaluate the place of 
levosimendan in the treatment of verapamil poisoning in humans. 
2.5.3 Other clinical effects 
Short-term levosimendan therapy of heart failure has been shown to have no tendency to increase 
the incidence of cardiac arrhythmias. A meta-analysis of cardiac arrhythmias by analysing ECG 
recordings from clinical studies on intravenously administered levosimendan in heart failure 
patients showed no difference between levosimendan and control groups in the occurrence of atrial 
fibrillation (AF), supraventricular tachycardia (SVT), or ventricular tachycardia (VT). In addition, 
the frequency of VT was similar and no torsade de pointes or sustained VT occurred (Lilleberg et 
al. 2004). In a recent open-label study in 50 patients with heart failure, given a 24-hour intravenous 
protocol once monthly for 6 months, no increase was seen in the incidence of supraventricular or 
ventricular beats or SVT and VT episodes in levosimendan group, compared with controls 
(Mavrogeni et al. 2007). However, in REVIVE II and SURVIVE trials, ventricular tachycardia as 
an adverse effect (AE) was statistically significantly more frequent with levosimendan than with 
placebo (Cleland et al. 2006), or occurred at a similar frequency with both levosimendan and 
dobutamine (Mebazaa et al. 2007). To sum up all of the i.v. studies, levosimendan seems to increase 
the occurrence of atrial fibrillation according to AEs (Levijoki, unpublished data). However, with 
respect to ventricular tachycardia, contradictory results have been reported in clinical trials. 
Levosimendan (0.5 mg four times daily) orally for 9 days in healthy subjects had no effects on 
blood coagulation (Antila et al. 2000). In addition, levosimendan has been shown to possess some 
anti-inflammatory and antiapoptotic properties. In patients with decompensated advanced heart 
failure after 48 hours compared with placebo, levosimendan induced a significant reduction in the 
concentration of interleukin-6 and a slight decrease in the level of tumor necrosis factor- (TNF-).
It also reduced soluble apoptosis mediators, such as soluble Fas and Fas ligand (Parissis et al. 2004; 
Paraskevaidis et al. 2005). 
2.5.4 Drug interactions 
Levosimendan seems to have no serious interactions with most of the drugs used in the treatment of 
CHF. The combination of levosimendan and dobutamine has been shown to be relatively safe and 
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effective in patients with severe heart failure (Nanas et al. 2004; Nanas et al. 2005). In cardiogenic 
shock patients requiring catecholamines, additive levosimendan infusion was shown to improve 
hemodynamics (Delle Karth et al. 2003). No pharmacodynamic interactions between levosimendan 
and warfarin, were seen in healthy volunteers (Antila et al. 2000). Levosimendan in combination 
with isosorbide-5 mononitrate was shown to have no major additive haemodynamic effects 
compared with each drug alone at rest. However, the response to an orthostatic heart rate test was 
potentiated with the combination of levosimendan and isosorbide-5-mononitrate in healthy subjects 
(Sundberg and Lehtonen 2000). When levosimendan was given in addition to carvedilol in healthy 
subjects, no additive positive inotropic, positive chronotropic, or effects on diastolic blood pressure 
were seen though the effect on systolic blood pressure was attenuated (Lehtonen and Sundberg 
2002). No major haemodynamic interactions between levosimendan and captopril, an ACE 
inhibitor, (Antila et al. 1996) or between levosimendan and felodipine, a calcium channel blocker, 
(Poder et al. 2003) have been observed in humans. Moreover, no pharmacodynamic interactions 
between levosimendan and ethanol, used as a diluent in the intravenous formulation, were found 
(Antila et al. 1997). Furthermore, levosimendan did not demonstrate any interaction with 
itraconazole (Antila et al. 1998), a potent inhibitor of CYP3A4 isoenzyme and an antifungal agent 
2.6 Summary of the effects of levosimendan on the cardiovascular 
system 
Levosimendan is defined as a inodilator agent based on its combined positive inotropic and 
vasodilator effects related to calcium sensitization and potassium channel opening. In addition to 
these properties it can evoke mitochondrial KATP channel opening, a unique assortment of 
mechanisms, which may be responsible for a positive synergistic effects on the whole 
cardiovascular system (Figure 6.). The abilities of levosimendan to improve myocardial function 
without increasing oxygen consumption practically at all and its property to enhance the perfusion 
of peripheral organs generates energetically favourable conditions for the restoration of impaired 
cardiac performance in addition to AHF also in ischemic heart disease, sepsis and perioperative 
cardiac support. 
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Figure 6. Summary of the effects of levosimendan on cardiovascular functions. ATP-dependent potassium channels 
(KATP); Large conductance calcium-activated potassium channels (BKCa); Voltage gated potassium channels (KV); 
Phosphodiesterase type-3 (PDE3); Troponin C (TnC); Ischemia-reperfusion (I-R); Left ventricle (LV); Right ventricle 
(RV). Modified from (Pinto et al. 2008) Curr Opin Anaesthesiol 21(2): 168-77. 
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3 AIMS OF THE STUDY 
The inodilatory effects of levosimendan have been described in many of the above-mentioned in
vitro and in vivo studies. It is a calcium sensitizer and an opener of ATP-dependent potassium 
channels and exerts its primary pharmacological effects via this unique double mechanism of 
action. There is another family of drugs with an inodilatory effect, the PDEIs, of which milrinone is 
a classical example. However, these drugs exert their inotropic and vasodilatory effects by 
a mechanism of action based on the increase of intracellular calcium, which has been associated 
with undesirable effects such as increased myocardial oxygen demand, cardiac arrhythmias, and 
mortality. However, it has been shown that levosimendan is an effective and potent PDE3 inhibitor, 
in vitro. The consequence of this PDE3 inhibition, in vivo is obscure, since levosimendan enhances 
cardiac contraction without increasing oxygen consumption, in contrast to the PDEIs. 
The present  ex-vivo experiments were designed to further characterize the mechanisms of action of 
levosimendan and to differentiate it from the inodilatory effects of the PDEIs. The model of isolated 
heart preparation was selected in order to study the dual effects of levosimendan in the target organ, 
possibly untangling the inotropic and vasodilatory effects. The experiments were conducted 
in guinea-pig isolated hearts because the cardiomyocytes of this species have a calcium 
handling similar to human myocytes. 
Five different study settings were designed in order to answer five main questions about the 
mechanisms of action of levosimendan: 
1. What is the role of cAMP- and cGMP-dependent protein kinases in the effects of 
levosimendan on cardiac contraction and coronary vasodilatation compared to the effects of 
the PDE inhibitor milrinone? 
2. How potent a inotropic agent and Ca2+-sensitizer is the active plasma metabolite of 
levosimendan, OR-1896, compared to levosimendan, and how selective inhibitors are these 
two agents on phosphodiesterase isoforms (PDE3 and PDE4)? 
3. Is the difference between the positive inotropic effects of levosimendan and its stereoisomer, 
dextrosimendan, correlated primarily to their stereoselective Ca2+-sensitizing effect or to 
their stereoselective phosphodiesterase inhibory functions?
4. What is the main vasodilatory mechanism of levosimendan in the coronary arteries? 
49
5. Is the inotropic mechanism of levosimendan energetically more advantageous than the 
mechanism of the PDE inhibitor, milrinone? 
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4 MATERIALS AND METHODS 
4.1 Experimental animals 
Adult guinea pigs of either sex (MOL-DUHA  in studies I and III-V and Duntley Hartley in study 
II, purchased from Mollegaard Breeding Center, Denmark), weighing 300–400 g were used. The 
guinea-pigs were housed in polycarbonate cages (Macrolone IV, Scanbur A/S, Denmark), in a 
thermostatically controlled room at 20 ± 1°C at a relative humidity of 50 ± 10%. The room was 
artificially illuminated from 06.00 to 20.00 hours. The guinea pigs received commercial, pelleted, 
guinea-pig feed (Altromin 3120, Chr.Petersen A/S, Denmark) autoclaved at 120°C and sterile, 
filtered tap water ad libitum. The study was conducted with the permission of the Animal Ethic 
Committee of Orion Pharma, in accordance with Finnish law and government regulations 
complying with the European Community guidelines for the use of experimental animals. 
4.2 Preparations 
4.2.1 Isolated heart 
The guinea-pig isolated heart was the most common preparation used in this study. Langendorff-
perfused heart is described in four studies, I, II, IV and V. Briefly, the guinea-pig was sacrificed and 
the heart was rapidly excised and rinsed in ice-cold oxygenated perfusion buffer. A cannula was 
inserted into the aorta and retrograde perfusion of the heart began as soon as the heart was placed in 
a thermostatically controlled moist chamber of the Langendorff apparatus. Modified Tyrode 
solution was used as a perfusion buffer. Most of the experiments were carried out under constant 
pressure conditions (50 mmHg). A latex balloon, attached to a stainless-steel cannula coupled to a 
pressure transducer, was placed in the left ventricle. The isovolumetric left ventricular pressure was 
recorded with a pressure transducer. Coronary flow was continuously recorded by an 
electromagnetic flow meter with a flow probe inserted above the aortic cannula. The HR and the 
left ventricular systolic and end-diastolic pressure of the heart were obtained from the digitised  
pressure signals. The left ventricular pressure signals were used to calculate the maximal positive 
and negative pressure derivatives (LV + dP/dtmax and LV  dP/dtmax, respectively). In studies II and 
V, the hearts were overpaced at 5 Hz. Furthermore, in study II, the experiment was carried out in 
the presence of constant coronary flow. Under these conditions, myocardial contractility could be 
increased either by an increase in the Ca2 +-sensitivity of the contractile system and/or by an 
increase in the amplitude of the Ca2 + transient due to phosphodiesterase inhibition. 
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4.2.2 Papillary muscle 
The papillary muscle preparation is described in studies I and III. Briefly, the right ventricular 
papillary muscle of the guinea-pig heart was mounted in an organ bath containing modified Tyrode 
solution for measurement of isometric tension. For pacing of the papillary muscle, the electrical 
pulses were conducted through platinum wire electrodes inserted on both sides of the muscle. The 
field stimulation occurred at 20% above threshold or at double the threshold voltage. A force-
displacement transducer was connected to a driver amplifier and a programmable scanner. The 
amplified signal was digitised at 1 kHz frequency by a programmable digitizer and the twitch 
tension was measured. 
4.2.3 Permeabilized cardiomyocytes 
Force measurements in permeabilized myocyte-sized preparations (skinned fibres) are described in 
studies I, II and III. Briefly, the calcium-sensitizing effect of levosimendan was investigated in two 
types of skinned fibers obtained either from unpretreated or isoprenaline-pretreated  isolated, 
spontaneously beating guinea-pig hearts. Fast and complete perforation of the cell membranes was 
achieved by retrogradely conducting saponin solution through the aorta into the coronary arteries of 
the heart. The fibers dissected from the papillary muscles were further mildly sonicated and treated 
with saponin. A slightly acidic pH of 6.7 was chosen in order to mimic the pH in the ischemic 
myocardium in which the calcium sensitivity is decreased and in which the benefits of 
levosimendan should be most prominent. The fibers were induced to contract in the calculated 
desired free pCa (Fabiato and Fabiato 1979). The absolute stability constants used were as reported 
by Fabiato (Fabiato 1981). At the beginning of the experiment, the fiber was stretched in ‘relaxing’ 
calcium free solution until the resting tension amounted to approximately 2% of the maximum force 
able to produce by the fiber. Then, the ‘relaxing’ solution was replaced with the ‘activating’ pCa 
5.8. solution which roughly corresponds to the intracellular cytoplasmic calcium during muscle 
contraction. When the tension produced by the fiber had reached a steady state, various 
concentrations of levosimendan were successively added to the solution. The maximum tension 
which was produced by the fiber at pCa 4.8 was determined after washing out the test compound. 
4.2.4 Inhibition of phosphodiesterase isoenzymes 
Inhibition of PDE is described in studies II and III. PDE III and IV were isolated from guinea pig 
hearts and from a human myeloid leukemia promonocytic cell line (U-937), respectively, to achieve 
high level PDE purity. The isolation procedure of PDE and the determination of their activities have 
been described earlier (Alajoutsijarvi and Nissinen 1987; Frodsham and Jones 1992; Torphy et al. 
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1992). Briefly, tissues were homogenized and the homogenate was centrifuged and further applied 
to DEAE cellulose columns and subsequently eluted with a linear gradient of sodium buffers. The 
collected fractions were subsequently assayed for cAMP and cGMP phosphodiesterase activity. The 
fractions containing phosphodiesterase activity were pooled to form isoenzyme specific pools. The 
effects of levosimendan, dextrosimendan, milrinone and OR-1896 on PDE activity were measured 
by using a liquid chromatograph system for on-line radiochemical detection of the formation of 
[3H]cAMP. PDE inhibitory potential determinations were performed in duplicate and the results are 
given as the means of the data from the individual test runs. The IC50-values for PDE inhibition 
were calculated. 
4.3 Statistical analysis 
In study I, ANCOVA (repeated measures) was used in order to verify that the selected 
concentration range for levosimendan and milrinone produced positive inotropy to the same extent 
in the isolated heart. The same statistical test was used when the hearts treated with the protein 
kinase inhibitors were compared with those exposed to levosimendan or milrinone alone. In all 
studies ANOVA (repeated measures), followed by Dunnett’s t-test was used, when the measured 
parameters were compared to the initial values. Statistical significance was accepted at P<0.05. The 
EC50 values from the sigmoidal dose-response data were calculated by using the curve-fitting 
algorithm of Microsoft® Office Excel program. 
4.4 Ethical statement 
The study was conducted with the permission of the Animal Ethic Committee of Orion Pharma, in 
accordance with Finnish law and government regulations complying with the European Community 
guidelines for the use of experimental animals.
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5 RESULTS 
The main results are summarized in table 3. 
5.1 Brief summary of the main effects in the separate studies 
Study I 
In the isolated Langendorff-perfused spontaneously beating guinea-pig heart, levosimendan and 
milrinone increased the left ventricular systolic peak pressure to almost the same extent. The 
inotropic and lusitropic effects of milrinone were mediated via PKA mediated phosphorylation, 
while the effects of levosimendan were not mediated via PKA up to its EC50. Furthermore, the 
stimulation of AC potentiated the positive inotropic effect of milrinone but not that of levosimendan 
in the papillary muscle. 
Study II 
In the isolated Langendorff-perfused paced guinea-pig heart, in the presence of constant coronary 
flow, levosimendan and OR-1896 were equally potent as positive inotropes. In the permeabilized 
cardiomyocytes, levosimendan and OR-1896 both increased isometric force production similarly. 
Furthermore, levosimendan was 40-fold more potent and a 3-fold more selective PDE3 inhibitor 
than OR-1896. 
Study III 
In the isolated guinea-pig papillary muscle preparation, levosimendan increased the twitch tension 
at 47 times lower EC50 value than dextrosimendan and in the permeabilized cardiomyocytes, 
levosimendan and dextrosimendan increased isometric force production due to Ca2 + -sensitization 
with a similar relative potency difference of 76. However, levosimendan was 427 times more potent 
PDE3 inhibitor than dextrosimendan.
Study IV 
In the isolated Langendorff-perfused spontaneously beating guinea-pig heart, levosimendan 
increased diastolic coronary flow velocity (DCFV) concentration-dependently, and this effect was 
noncompetitively antagonized by glibenclamide, whereas the effects of pinacidil were antagonized 
competitively by glibenclamide. In the presence of glibenclamide, the positive inotropic and 
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chronotropic effects of levosimendan were unaltered. The effect of a PKC inhibitor, BIM and 
levosimendan on DCFV was additive. 
Study V 
In the isolated Langendorff-perfused paced guinea-pig heart, perfusion with levosimendan 
consumed proportionally less oxygen than perfusion with milrinone, while the compounds 
increased the mechanical performance of the heart equally. 
5.2 Isolated Langendorff-perfused heart 
The inotropic and vasodilatory effects of levosimendan and its active metabolite, OR-1896, were 
studied in retrogradely perfused isolated guinea-pig hearts and compared to the effects of milrinone 
and pinacidil. In the paced hearts, levosimendan and OR-1896 were equally potent positive 
inotropes with very similar concentration dependences with a slightly lower EC50 value for 
levosimendan than that for OR-1896 (15 ± 2 nM vs 25 ± 1 nM, P < 0.05). They were also equal 
efficacious, increasing the left ventricular + dP/dtmax  by 26 ± 4% and 25 ± 3% (mean ± S.E.M.), 
respectively (study II). Compared to milrinone, levosimendan was 10 to 30 times more potent than 
milrinone as a positive inotropic and lusitropic agent. The maximum increase in left ventricular 
systolic pressure (LVSP) was 24 ± 10% in the levosimendan-treated group and 20 ± 10% in the 
milrinone-treated group. The maximum increase in contractility (+dP/dt max) was 30 ± 10% and 28 
± 11% and the maximum increase in relaxation (dP/dt max) was 36 ± 17% and 37 ± 14% in the 
levosimendan and milrinone groups, respectively (study V). In the spontaneously beating hearts, 
levosimendan was 10 to 20 times more potent as an inotropic agent than milrinone. The EC50
concentration for the elevation in LVSP by levosimendan was about 0.03 μM and that for milrinone 
was about 0.6 µM. However, levosimendan and milrinone increased the left LVSP almost equally, 
levosimendan maximally by 17 mmHg (+19%) at 0.3 mM and milrinone maximally by 14 mmHg 
(+15%) at 3 mM (study I). The PKA inhibitor, KT5720 (1 μM) inhibited the contraction (LVSP and 
+dP/dtmax) of levosimendan at the highest studied concentrations ( 0.1 μM). Instead the inotropic 
effects of milrinone, were inhibited totally by KT5720. The effects of KT5720 on relaxation (-
dP/dtmax) of levosimendan and milrinone were similar to those on contraction. The PKG inhibitor, 
KT5823 (1 μM), did not affect statistically significantly the increasing effect of levosimendan or 
milrinone on the contraction or relaxation (study I). The PKC inhibitor, BIM, did not have any 
effects either on the contraction or relaxation in the levosimendan group (study IV). 
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In spontaneously beating guinea-pig hearts, levosimendan concentration-dependently increased the 
heart rate (HR) to the same extent in the absence and presence of KT5720 or KT5823. In all groups, 
a maximum increase of 27–30% was seen at 1 μM levosimendan. The magnitude of the positive 
chronotropic effect of milrinone (0.1–10 mM) was comparable to that of levosimendan (0.01–1 
mM), but unlike the situation with levosimendan, the maximum effect was not reached at the 
concentrations used (study I). Moreover, the PKC inhibitor, BIM, did not have any effects on the 
HR in the levosimendan group (study IV). 
Levosimendan alone increased the coronary flow concentration-dependently and maximally by 64% 
at 1 μM. The increase in coronary flow by milrinone alone did not differ from that induced by 
levosimendan except that the maximum effect was not reached at the milrinone concentrations used 
(study I). Also the increase in the DCFV by levosimendan reached a maximum effect at 1 μM. The 
effect of pinasidil on DCFV was equal with levosimendan (study IV). The total change in the 
oxygen consumption was significantly lower during levosimendan than the corresponding value 
during milrinone perfusion. Furthermore, the maximum increase in oxygen consumption was 10 ± 
4% in the levosimendan group compared with 38 ± 15% in the milrinone group (P = 0.031 between 
the concentration-dependent effects of the two drugs on VO2) (study V). The response to 
levosimendan or milrinone was slightly and to the same extent decreased in the presence of KT5720 
(1 μM). In contrast, the levosimendan-induced increase in coronary flow was almost doubled in the 
presence of KT5823 (1 μM), whereas KT5823 did not alter the milrinone-induced increase in 
coronary flow (study I). The effect of levosimendan on DCFV was noncompetitively (nonparallel 
shift of the concentration-response curve to the right) antagonized by glibenclamide on the contrary 
to pinacidil, which was antagonized competitively (parallel shift of the concentration-response 
curve to the right) by glibenclamide. Furthermore, the concentration-response curve of 
levosimendan in the presence of the BIM, was markedly potentiated (study IV). In addition, it 
should be mentioned that glibenclamide alone decreased the DCFV and BIM increased it, while 
KT5720 and KT5823 had no effects on the baseline DCFV. 
5.3 Papillary muscle 
The concentration–response curve of levosimendan on twitch tension displayed a bell-shaped form 
and was markedly dependent on the stimulus strength used in the pacing of the papillary muscle. No 
such similar phenomenon was seen with milrinone (study I). The EC50 concentrations for 
levosimendan were 0.1 and 0.3 μM when the papillary muscles were paced at 100% or at 20% 
above threshold voltage, respectively. The maximum increases of 330 mg (+127%) and 90 mg 
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(+45%) in twitch tension were reached at 1 and 3 μM, respectively. The EC50 value for milrinone 
was about 2 μM independently of the stimulus strength used. The maximum increase of 240 mg in 
twitch tension induced by milrinone was also not affected by the stimulus strength (study I). 
Moreover, twitch tension increased with EC50 values of 60 nM for levosimendan compared to 2.8 
μM for dextrosimendan. Hence, the two enantiomers exhibited a 47 times potency difference in 
their positive inotropic effects (study III). 
In guinea-pig papillary muscles paced at twofold threshold voltage, forskolin (0.1 μM) increased 
twitch tension due to stimulation of the cAMP synthesis. The levosimendan-induced increase in 
twitch tension was not markedly changed in the presence of forskolin, while the positive inotropic 
effect of milrinone was almost doubled when it was combined with forskolin (study I). The initial 
twitch tension changed less than 10% by treatment with the 1-AR antagonist, atenolol (1 μM). 
However, atenolol abolished the stimulus sensitivity of the twitch tension and thereby eliminated 
the stimulus strength dependency of the inotropic response to levosimendan. Furthermore, 
levosimendan at 1 μM and milrinone at 10 μM increased twitch to the same extent (+180% to 
+190%) when these concentrations were tested before isoprenaline. After wash-out of isoprenaline, 
in percentage terms, milrinone was as efficacious as before isoprenaline, but the levosimendan-
induced increase in twitch tension was reduced to 78% of pre-isoprenaline values (study I).
5.4 Permeabilized cardiomyocytes 
In permeabilized guinea-pig cardiomyocytes, levosimendan (0.3–10 μM) concentration-
dependently increased the calcium-induced tension at pCa 5.8 from 7% to 26% of the maximum 
tension produced by the skinned fibers at pCa 4.8 (study I). In the comparison of levosimendan with 
OR-1896, both compounds increased isometric force production at pCa 6.2 by 51% ± 7% and 52% 
± 6%, with EC50 values of 8 ± 1 nM and 36 ±7 nM, respectively (study II). In addition, 
levosimendan and dextrosimendan increased isometric force production (at pCa 6.2) with EC50
values of 8.4 nM and 0.64 μM, respectively, i.e. a relative potency difference of 76 (study III). 
However, when the permeabilized cardiomyocytes were obtained from isoprenaline-pretreated (0.1 
μM, for 10 min) hearts, the levosimendan-induced increase in tension of the skinned fibres was only 
from 6% to 16% of the maximum tension (study I). 
5.5 Purified PDE enzymes 
Increasing concentrations of levosimendan or OR-1896 decreased the PDE3 activity in a dose-
dependent manner. The half-maximal inhibition of PDE3 was achieved at a concentration (IC50) of 
57
2.5 nM by levosimendan, while in the case of OR-1896, the IC50 was 94 nM. Similarly to the results 
with PDE3, increasing concentrations of levosimendan or OR-1896 also progressively decreased 
the PDE4 activity. However, to achieve half maximal inhibition of PDE4, significantly higher drug 
concentrations were required. The IC50 value for levosimendan was 25 μM, comparison to 286 μM 
for OR-1896 (study II). Furthermore, levosimendan was a 427 times more potent PDE3 inhibitor 
than dextrosimendan, with IC50 values of 7.5 nM, and 3.2 μM, respectively (study III).
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6 DISCUSSION 
The main conclusion emerging from the present study is the concept that levosimendan possesses of 
two main mechanisms of action, an inotropic effect via calcium sensitization and a vasodilatory 
effect mediated through the opening of the KATP channels. However, levosimendan was found to be 
a potent PDE3 inhibitor, a finding which is at odds with the fact that levosimendan does not 
increase intracellular calcium concentration [Ca2+]i and oxygen consumption in proportion to its 
inotropic effect. This dilemma is discussed in the following chapters. 
6.1 Inotropic effects
In the present study, the economy of the contraction was shown to be more advantageous in 
levosimendan-perfused hearts than in milrinone-perfused hearts (study V). Previously, Lancaster 
and Cook have shown that levosimendan produced an increase in cell shortening in guinea-pig 
cardiomyocytes without affecting the [Ca2+]i transient or the Ca2+ content of the sarcoplasmic 
reticulum at clinically relevant concentrations  0.1 μM (Lancaster and Cook 1997). However, 
other studies have revealed that levosimendan can increase the calcium transient already at low 
inotropic concentrations and emphasized its dual mechanism of action in its positive inotropic 
effects (Sato et al. 1998; Takahashi and Endoh 2005). In canine ventricular trabeculae loaded with 
aequorin, the positive inotropic effect of levosimendan up to 10 μM was associated with an increase 
in Ca2+ transients (Takahashi and Endoh 2005). On the other hand, in isolated failing human 
myocardium, levosimendan induced moderate inotropic effects without any increased intracellular 
calcium transients (Hasenfuss et al. 1998). Levosimendan increased twitch tension statistically 
significantly and aequorin light emission statistically nonsignificantly at a concentrations of 0.3 and 
1μM. In comparison, at concentrations of 10 μM and 100 μM, milrinone increased both twitch 
tension and aequorin light emission statistically significantly. Therefore, these findings support the 
concept that the positive inotropic effect originates predominantly from myofilament calcium 
sensitization. 
In the present study, levosimendan was found to be 10–20 times more potent as a positive inotropic 
compound than the PDE inhibitor, milrinone, in isolated guinea-pig heart. Previously, the positive 
inotropic effect of levosimendan has been shown to be sensitive to carbachol (Sato et al. 1998). The 
inhibitory action of carbachol may be exerted selectively on the cAMP mediated positive inotropic 
effect, because it is virtually unaffected by the inotropic effect of other drugs e.g. -adrenoceptor 
agonists and cardiac glycosides, that do not involve the generation of cAMP (Endoh 1995). 
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However, the PKA inhibitor, KT5720, did not antagonise the increase in LVSP produced by 
levosimendan at concentrations up to its EC50. This effect of levosimendan contrasts with that of 
milrinone, which was devoid of the positive inotropic effect in the presence of KT5720, i.e. 
evidence that PDE inhibition is the major mechanism of action of milrinone. In heart failure 
patients, 95–98% of levosimendan is bound to plasma proteins and therefore its therapeutically 
active free plasma concentration is less than 0.02 μM (Sandell et al. 1995). Additionally, during the 
treatment of acutely decompensated heart failure, a maximal free concentration of 3–6 nM of 
levosimendan has been measured (Kivikko et al. 2002). Therefore, the concentration range used in 
the present study was at the clinically relevant level. In guinea-pig papillary muscle, the EC50 value 
of levosimendan for the inotropic effect was about 3 times higher than in isolated heart, being 
comparable to the effects in isolated human cardiac muscle strips. In canine ventricular trabeculae, 
the EC50 value of levosimendan to promote contraction was even higher. 
Compartmentation of cAMP is thought to generate the specificity of Gs-coupled receptor activation 
in cardiac myocytes. The PDEs have a major role in this signal cascade by preventing cAMP 
diffusion. For example, selective inhibition of PDE3 by cilostamide and of PDE4 by Ro 20-1724 
have both been shown to potentiate 1-AR cAMP signals, whereas the Glu-R activated cAMP level 
was increased only by PDE4 inhibition. Furthermore, cAMP levels increased by PGE1-R and 2-
AR stimulation only when PDE3 and PDE4 were blocked (Rochais et al. 2006). In the recent study 
with cilostamide and Ro 20-1724 in adult rat ventricular myocytes, Leroy et al (Leroy et al. 2008) 
revealed that PDE3 inhibition has a direct inotropic effect on basal contractility and PDE4 
inhibition causes inotropic responses in the presence of -AR stimulation. Thus, they hypothetized 
that PDE3 can regulate a “constitutive” cAMP pool linked to contractility, whereas PDE4 regulates 
the cAMP microdomains mobilized by -AR stimulation.  
In study II, the selectivity factors for levosimendan and OR-1896 to inhibit PDE3 in preference to 
PDE4 were 10000 and 3000, respectively. The corresponding value for milrinone has been found to 
be only 14 (de Cheffoy de Courcelles et al. 1992). Leroy et al observed that when PDE4 was 
inhibited, PDE3 became the predominant enzyme to hydrolyze membrane and cytosolic cAMP, as 
well as regulating ICa,L recovery (Leroy et al. 2008). Therefore, PDE4 seems to be able to 
compensate for PDE3 inhibition, at least in the cytosol and in sites near the L-type Ca2+ channels. 
Moreover, PDE4D subtype is related to the A kinase anchoring protein-organized signaling 
complexes (Dodge-Kafka et al. 2006), thus activation of PDE4 can be regulated by PKA. This 
could explain why KT5720 did not antagonize the effects of levosimendan, a very selective PDE3 
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inhibitor, and therefore, the role of PDE3 inhibition in levosimendan induced inotropy seems to be 
modest.  
Thus, one could speculate that when only one phosphodiesterase isoenzyme is inhibited and one 
signal cascade is blunted, cAMP is presumably metabolized by the other phosphodiesterase 
isoenzymes and another inotropic signal cascade is active. In addition, PDE inhibitors with poor 
PDE selectivity have been shown to be more potent elevators of intracellular cAMP in 
cardiomyocytes, supporting the concept of additive effect on simultaneous activation of parallel 
inotropic signal cascades (Cone et al. 1999; Shakur et al. 2002). It is notable that in rapid pacing-
induced heart failure in dog, PDE3 mRNA and activity had decreased, whereas PDE4D was 
unchanged, another indication that the role of PDE3 inhibition is not very significant in the effects 
of levosimendan (Smith et al. 1997). Moreover, dextrosimendan, the stereoisomer of levosimendan, 
had 47 times less positive inotropic effect in papillary muscle preparations and 76 times less effect 
on the contractile apparatus, the EC50-values being comparable in permeabilized cardiomyocytes. 
However, the PDE3 inhibitory activities of the two stereoisomers differed by 427 fold (study III).
Furthermore, the positive inotropy by levosimendan was found to depend on the strength of 
electrical stimuli. This phenomenon was not seen with milrinone, indicating that it was not due to 
PDE inhibition and cAMP. However, the 1-AR antagonist, atenolol, decreased the sensitivity of 
twitch tension to the stimulus strength. Thus, the high stimulus strength may have enhanced the 
release of noradrenaline from adrenergic nerve terminals, leading to activation of 1-ARs and to the 
direct Gs-protein-mediated opening of calcium channels (Rochais et al. 2006). In this respect, a 
contributory role for PDE3 inhibition cannot be excluded. Otherwise, the high stimulus strength 
finally increases intracellular calcium transient, which in turn increases the number of activated 
cTnC molecules. Since the binding of levosimendan to cTnC is calcium-dependent, there will be an 
increased number of binding sites when more cTnC molecules become activated. Therefore, the 
calcium sensitization and subsequently the positive inotropy caused by levosimendan can be 
potentiated when a high stimulus strength is used. Moreover, forskolin activates AC and further 
increases cAMP and the intracellular calcium transient. Theoretically, selective inhibition of PDE3 
should potentiate the stimulatory effect of forskolin on 1-AR associated AC. However, milrinone, 
but not levosimendan, was able to potentiate the effect of forskolin. Alternatively, the increased 
intracellular calcium content may activate more cTnC molecules and this could then potentiate 
calcium sensitization evoked by levosimendan. 
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Isoprenaline, in turn, induces PKA-mediated phosphorylation of cTnI which leads to an alteration in 
the conformation of cTnC (Rapundalo et al. 1989; Wattanapermpool et al. 1995). This may inhibit 
the binding of levosimendan to cTnC and thereby antagonize its positive inotropy. The present 
study with isoprenaline showed that the positive inotropy induced by levosimendan at the 
concentration giving a maximum effect was decreased by 60–70% in isoprenaline-pretreated 
muscles. In contrast, the inotropic response to milrinone was not altered by similar isoprenaline 
pretreatment. Thus, cTnC seems to be the target protein for levosimendan also in the intact muscle 
and most of its positive inotropic properties may then be due to calcium sensitization. Furthermore, 
when levosimendan was added to the buffer, the positive inotropy evoked by isoprenaline had 
completely expired due to its wash-out. Therefore, the effect of levosimendan was affected only by 
the altered phosphorylation of contractile proteins and no longer by the increased intracellular 
calcium transient. When forskolin and levosimendan were investigated simultaneously, also the 
increased calcium transient induced by forskolin influenced the response to levosimendan. These 
differential experimental results explain why the action of levosimendan was altered in different 
ways in the forskolin and isoprenaline studies. 
Acceleration of the relaxation induced by levosimendan could be due to cAMP accumulation 
induced by PDE3 inhibition, because like the contraction, it is inhibited by carbachol (Boknik et al. 
1997; Sato et al. 1998). However, the present study revealed that in the presence of the PKA 
inhibitor, KT5720, levosimendan did not impair relaxation but increased the negative dP/dtmax. The 
milrinone-induced increase in the negative dP/dtmax was instead markedly antagonised by KT5720. 
However, the effect was not completely abolished probably because of the increase in HR, which 
was not abolished by KT5720 (study I). Moreover, levosimendan does not impair relaxation either 
under normal conditions or during acidosis (Takahashi and Endoh 2005). In the failing heart, 
cAMP-mediated signaling is weakened (Feldman et al. 1987), and therefore, it is probable that the 
increase in Ca2+-sensitivity could be more pronounced than any PDE3 inhibitory action in failing 
ventricular myocardium (Hasenfuss et al. 1998). Furthermore, during acidosis, where cAMP loses 
its effectiveness, lack of impairment of relaxation due to the Ca2+-dependent nature of the binding 
of levosimendan to troponin C is even more pronounced than in normal conditions (Haikala et al. 
1995).
6.2 Vasodilatory effects 
In the present study, levosimendan increased coronary flow both in the spontaneously beating heart 
(study I) and in the overpaced heart (study V). In their classical work, Braunwald et al (Braunwald 
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et al. 1958) demonstrated that oxygen consumption (MVO2) is the major determinant of coronary 
blood flow. Heart rate (HR), in turn, is one of the main determinants of MVO2. Therefore, any 
increase in HR is in proportion to the increase in CF and MVO2. Even though levosimendan 
increased HR and CF in a parallel manner in the spontaneous beating hearts, MVO2 was not 
increased in parallel with CF after levosimendan administration in the paced hearts. Thus, 
levosimendan had a direct vasodilatory effect on coronary veins. Moreover, the PKG inhibitor, 
KT5823 potentiated the levosimendan- but not the milrinone-induced increase in CF i.e. the 
coronary dilatory mechanism of action of levosimendan differs from that of milrinone and it does 
not seem to be mediated through the activation of PKG. The K+ current through the delayed 
rectifier K+ channels should be limited during PKG inhibition since these channels are normally 
activated by PKG (Sperelakis et al. 1994; Ko et al. 2008). In this situation, the efflux of K+ ions 
may occur more through the KATP channels, which may potentiate any vasodilatory effect mediated 
through these channels. 
Patch clamp studies in rat mesenteric arterial cells have revealed that levosimendan can open KATP
channels (Yokoshiki et al. 1997). In study IV, it was shown that glibenclamide antagonized the 
increase in DCFV induced by levosimendan, demonstrating that the opening of the KATP channels 
was the mechanism of action of the observed vasodilatory effect. Pinacidil was three times more 
efficacious and ten times less potent than levosimendan at increasing DCFV. Moreover, 
glibenclamide antagonized the coronary dilation induced by levosimendan and pinacidil in two 
different ways, suggesting that these two drugs may have different binding sites on the KATP
channels. The effect of pinacidil was antagonized competitively by glibenclamide, as expected 
(Nielsen-Kudsk et al. 1996), whereas levosimendan was inhibited in a non-competitive manner. 
One possible explanation for this result is that levosimendan opens the channel indirectly or, 
alternatively, interacts with different subtypes of glibenclamide-sensitive channels (Quast and Cook 
1989; Quast et al. 1994; Adebiyi et al. 2008). However, the effect of levosimendan on KATP channel 
was also revealed previously in single-channel recordings (Yokoshiki et al. 1997), which suggests 
that it does have a direct effect. An alternative explanation is that levosimendan has another 
vasodilatory mechanism. 
As previously mentioned, the specific BKCa channel blocker, IBTX suppressed the maximum effect 
of levosimendan, and the KV channel blocker, 4-AP significantly shifted the concentration-
response curve to the right in isolated porcine epicardial coronary arteries, indicating that the 
vasorelaxing mechanism of levosimendan involves the activation of voltage-sensitive and, at large 
concentrations, of calcium-activated potassium channels (Pataricza et al. 2003). In addition, 
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levosimendan is believed to be able to relax porcine coronary arteries through calcium 
desensitization, interacting with smooth muscle EF-hand proteins, such as, calmodulin, the 
regulatory myosin light chains, or S100 proteins (Bowman et al. 1999). This effect was seen at ten 
times higher concentrations (0.1–10 μM) than those used in the present study (0.01–1 μM). 
However, this could explain the non-competitive inhibitory mode of action of glibenclamide on the 
increase in DCFV by levosimendan. 
The role of PDE3 inhibition cannot be totally excluded, since levosimendan has been shown to 
potentiate the relaxant effect of cAMP-stimulation evoked by isoprenaline (Gruhn et al. 1998). On 
the other hand, the PKA inhibitor, KT5720 did not antagonize the effect of levosimendan on CF 
(study I). Nevertheless, the effect of milrinone on CF was also not antagonized by KT5720. This 
can be explained by the differences in the MVO2 of the contraction-relaxation cycle between 
levosimendan and milrinone. In isolated heart, milrinone increased CF in parallel with MVO2 , in 
contrast to levosimendan, which increased CF independently of MVO2 (study V). In addition, in 
patch clamp studies, a non-specific protein kinase inhibitor, H-7 did not prevent the 
hyperpolarisation and stimulation of K+ current by levosimendan in mesenteric arterial myocytes 
(Yokoshiki et al. 1997). Thus, it seems unlikely that  PDE3 inhibition plays any major role in the 
vasodilatory effects of levosimendan. 
The concentration response of levosimendan was markedly potentiated in the presence of the PKC 
inhibitor, bisindolylmaleimide (BIM). PKC is a mediator of the effects of several vasoconstrictors 
on K+ channels (Ko et al. 2008) and it is known that inhibition of the PKC-mediated 
phosphorylation of the KATP channels in the isolated rabbit heart can evoke a vasodilatory effect 
(Pongo et al. 2001). Therefore, it could be hypothesized that the potentiation of the increase in 
DCFV was due to a specific binding and action of levosimendan on the non-phosphorylated form of 
the KATP channels. In the present study, glibenclamide did not antagonize the effect of 
levosimendan on the contractile parameters of the heart, indicating that its action on the KATP
channels was not indirectly mediated through the changes in the contraction parameters. Rather it is 
directly mediated via the coronary vasculature smooth muscle relaxation, since glibenclamide 
markedly antagonized the levosimendan-induced increase in DCFV. On the contrary, the negative 
inotropic responses of pinacidil were shown to competitively antagonized by glibenclamide (Lau 
1992).
In addition,  KATP channel activation is an important mediator of ischemic preconditioning (Gross 
and Auchampach 1992; O'Rourke 2004). The stimulation of KATP channels has been shown to 
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decrease myocardial infarct size (Gross and Auchampach 1992) and it can also enhance recovery of 
the stunned myocardium (Yao and Gross 1994). Moreover, the studies of Kersten et al. (Kersten et 
al. 2000) showed that levosimendan decreased the myocardial infarct size in coronary-ligated dogs 
and that the effect was mediated through KATP channels. Although, vasodilatation may be beneficial 
in ischemia, it seems that mitoKATP channels are especially linked to the cardioprotective effects 
(Nishida et al. 2009). The effects of levosimendan on ischemia-reperfusion were not studied in the 
present experiments. However, we have noticed in guinea-pigs, that levosimendan could prevent the 
myocardial stunning in the isolated, Langendorff-perfused heart after global ischemia (Kaheinen, 
unpublished data). 
6.3 Limitations of the methods and proposal for future studies 
Isolated Langendorff-perfused heart was the most widely used preparation used in this study. It was 
also the most complex method and has a number of limitations, which have been previously 
reviewed extensively (Sutherland and Hearse 2000). Briefly, the lack of any oxygen carrier in the 
salt solution requires the use of high oxygen partial pressure to saturate the perfusion solvent and 
this causes considerably higher basal coronary flow than that normally present in vivo. A 
consequence of this unnatural coronary perfusion is a deterioration of the contractile function 
during the experiment. In study IV, the incomplete oxygen supply was seen as a decrease in basal 
CF in the presence of glibenclamide, indicating at least partially open KATP channels. Moreover, use 
of salt-base buffer lacking plasma proteins can cause edema, which could induce a decrease in 
coronary flow. It took at least 1-2 h to reach a stable function of the heart and achieve a balance 
between oxygen supply and need (seen as stable coronary flow, oxygen consumption, and 
contractility parameters) in the present study. Subsequently, it was found that addition of pyruvate 
as well as glucose in the perfusate could shorten the stabilization period, but pyruvate was not used 
in the present study. Furthermore, in constant flow mode, unlike constant pressure perfusion, 
autoregulatory mechanisms are bypassed, which does not automatically ensure that the perfusate 
would be delivered uniformly to the whole heart as it responds to changes in heart rate or work. In 
addition, in the intact heart, the atria and sino-atrial node are not perfused by coronary vessels but 
by extracardiac vessels, which are damaged when the heart is excised for perfusion. This makes it 
difficult to maintain essential oxygen supply for the sino-atrial node and a stable heart rate. 
However, this problem can be avoided by pacing the heart, which was done in the part of the study 
(studies II and V). 
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Although, the stature of PDE3 inhibition on the inotropic and vasodilatory effects of levosimendan 
was shown to be slight in the experimental settings used in the present study, its final status still 
remains unclear. In addition, the intracellular calcium content was not measured. Simultaneous 
measurement of Ca2+ transient with alteration of contractile function in the isolated heart perhaps 
would have made it possible to elucidate the mode of action of levosimendan, especially the role of 
PDE inhibition. Interestingly, Sun et al (Sun et al. 2007) have recently published a study using 
PDE3A and PDE3B gene knockout (KO) mice. They proposed that PDE3A is the main subtype of 
PDE3 expressed in cardiac ventricular myocytes, and that it is responsible for the functional 
changes caused by PDE3 inhibition. Thus, further studies are warranted to examine the effects of 
levosimendan in these mice, though the species differences may complicate comparisons with the 
present studies. In addition, studies examining the mechanism of action behind the stroke-
preventive effects of levosimendan would be scientifically interesting, in addition to being 
beneficial for future drug design. 
6.4 Overall clinical aspects 
In drug development, two characteristics come before all others, efficacy and safety in patients. In 
clinical use, the originally designed indication may be changed and/or new off-label indications 
stand out. That is what has happened to levosimendan. As mentioned above, it is approved for 
short-term treatment of acutely decompensated chronic heart failure. However, in the clinic, 
levosimendan has been demonstrated to have beneficial effects in ischemic heart disease and also 
against septic shock. It has been also demonstrated that levosimendan can be used as a bridge 
therapy for the perioperative cardiac support e.g. it facilitates weaning of patients from 
cardiopulmonary bypass (Eriksson et al. 2009). The last-mentioned indication is possible because of 
the ability of levosimendan to improve myocardial function without substantially increasing oxygen 
consumption.
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7 SUMMARY AND CONCLUSIONS 
The mechanisms of action of an inodilator, levosimendan, were studied in isolated guinea-pig heart 
preparations. Levosimendan was shown to be a potent inotropic agent in isolated Langendorff-
perfused heart and right ventricle papillary muscle. In permeabilized cardiomyocytes, it was proved 
to be a potent calcium sensitizer in contrast to its positive enantiomer, dextrosimendan. Despite its 
very selective PDE3 inhibitory properties in purified enzyme preparations, the inotropic effect of 
levosimendan was observed to be mainly mediated through calcium sensitization also in the isolated 
heart as well as the papillary muscle preparations at clinically relevant concentrations. The effects 
of levosimendan differed considerably from the effects of milrinone. In particular, the energy 
efficiency of the contraction was shown to be advantageous in levosimendan-perfused hearts 
compared to milrinone-perfused hearts. Levosimendan binds to cardiac troponin C in a calcium-
dependent manner and thus, does not impair the relaxation, as confirmed in the present study. 
Furthermore, the vasodilatory effect of levosimendan was shown to be mediated mostly through the 
opening of the KATP channels in the isolated heart. 
The main findings and conclusions of the present study are as follows: 
1. The main inotropic and vasodilatory mechanisms of action of levosimendan are not related 
to the PKA mediated phosphorylation. 
2. Levosimendan and OR-1896 are equally potent as positive inotropes and Ca2+-sensitizers 
and reveal highly selective PDE3 inhibitory properties. 
3. Levosimendan and its positive stereoisomer, dextrosimendan seem to exert their positive 
inotropic effects via a stereoselective Ca2+-sensitizing mechanism and not via stereoselective 
inhibition of PDE3.
4. The main vasodilatory mechanism in coronary veins is the opening of the KATP channels in 
the vascular smooth muscle. 
5. The inotropic mechanism of levosimendan is energetically more advantageous than the 
mechanism of the PDE inhibitor milrinone, this being seen as low oxygen consumption in 
relation to the produced force of contraction. 
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